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ABSTRACT 
 
Metformin is the most common drug used against type 2 diabetes 
mellitus. However, it was only recently shown, in human and rat 
hepatocytes, that metformin-like 5-aminoimidazole-4-carboximide 
ribonucleoside (AICAR), acts via activation of the AMP-activated protein 
kinase (AMPK), an enzyme that plays a central role in lipid metabolism. 
Although it is well known that metformin is used in the treatment of type 
2 diabetes and results in significant fat loss, no study has investigated 
the effects of this drug on adipocytes. In this report I studied the effects 
of metformin on the formation of fat deposits in mouse 3T3-L1 pre-
adipocytes, as well as its effects on the activation of AMPK in these cells. 
Our results suggested that metformin significantly inhibits the 
transformation of pre-adipocytes into adipocytes. This is achieved via the 
inhibition of intracellular lipid accumulation during adipogenesis. In 
addition to its inhibition of intracellular lipid accumulation, metformin 
induced a significant increase in the phosphorylation of AMPK. 
It has been shown that AMPK activation with AICAR results in the 
inhibition of the nuclear factor-κB (NF-κB) induced gene expression. Since 
NF-κB is the key nuclear factor used by HIV-1 during the initiation of its 
gene transcription, I investigated the possibility of inhibiting HIV-1 
replication in U1 cells with metformin and AICAR. I observed that AICAR 
and metformin inhibit HIV-1 replication in U1 cells. This inhibition was 
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paralleled by the accumulation of NF-κB in the cytoplasm of AICAR and 
metformin treated cells, and at the same time by a significant decrease in 
the concentration of this nuclear factor in the nucleus of these cells. 
However, I failed to observe any phosphorylation of AMPK by metformin 
and AICAR in U1 cells. 
In conclusion, metformin inhibits adipogenesis in mouse adipocytes and 
this inhibition is likely to take place via the activation of AMPK. AICAR and 
metformin have inhibitory properties against HIV-1 replication. However, 
this inhibition does not seem to be by the activation of AMPK.  
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           LITERATURE REVIEW 
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1.1    Introduction 
 
Adenosine monophosphate-activated protein kinase (AMPK) is a major 
regulator of cellular energy metabolism. AMPK is activated under 
conditions such as exercise and starvation, that decrease the 
intracellular concentration of adenosine triphosphate (ATP) and increase 
the concentration of adenosine monophosphate (AMP) [1]. The ratio 
(ATP)/ (AMP) regulates the activation of AMPK i.e. a decrease in the ratio 
activates AMPK while an increase inactivates the enzyme. In addition to 
regulating intracellular energy homeostasis, AMPK modulates whole 
body energy expenditure by controlling processes such as food intake. 
It has been shown that in the region of the rat hypothalamus that 
controls food intake and satiety, AMPK inhibition by leptin and insulin 
inhibits food intake, while its activation by the gut hormone ghrelin 
stimulates this process [2].  
AMP regulates AMPK activation via allosteric control. The binding of 
AMP to AMPK induces a change in conformation that makes AMPK 
susceptible to phosphorylation at residue threonine-172 (Thr-172) of its 
catalytic subunit, or a-subunit, by an upstream kinase known as AMPK 
kinase (AMPKK) [1, 3, 4]. LKB1 has been identified as one of the 
upstream kinases that phosphorylate AMPK [1, 5]. The activated AMPK 
phosphorylates and inhibits key enzymes involved in pathways that 
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consume ATP, such as fatty acid and cholesterol biosynthesis, and at 
the same time it activates pathways that produce ATP, such as the b-
oxidation of fatty acids and glycolysis (figure 1.1).  
Gene transcription is also inhibited by AMPK under conditions of low 
ATP concentration, as this process requires energy [6]. AMPK inhibition 
of gene expression is via inhibition of transcription factors such as 
Nuclear factor-kB (NF-kB) and hepatocyte-specific nuclear factor 4a 
(HNF4a) [1, 6]. It has been shown that NF-kB induced gene expression 
can be suppressed by AMPK activation with 5-aminoimidazole-4-
carboximide ribonucleoside (AICAR), in human umbilical vein 
endothelial cells (HUVEC) [1]. This opens up the possibility of using the 
activation of AMPK against viruses such as the human 
immunodeficiency virus type 1 (HIV-1)  which depend on NF-kB to 
induce their gene transcription [7].  
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Figure 1.1: Pathways inhibited by AMPK activation are shown in red. 
Pathways that activate AMPK and those that are activated by AMPK 
activation are shown in green [1] ( eNOS: endothelial nitrous oxide 
synthase). 
 
Deficiencies in the AMPK signaling system have been implicated in many 
metabolic disorders, amongst them type 2 diabetes (T2DM) and obesity 
[8]. 
 Metformin is a drug that is widely used against T2DM and insulin 
resistance, and it is believed to act via activation of AMPK [9].  
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1.2         AMPK structure  
1.2.1        AMPK-isoforms  
 
AMPK is an αβγ-heterotrimer. The α-subunit is the catalytic subunit, 
whilst the β-and γ-subunits are non-catalytic, but they are required for 
the stability of the heterotrimer and for substrate specificity. There are 
two α-subunits, α
1 
and α
2
, two β-subunits, β
1
 and β
2
, and three γ-subunits, 
γ
1
, γ
2
, and γ
3
. All possible combinations of these AMPK subunit isoforms 
give active complexes. AMPK is activated by phosphorylation at the 
threonine-172 residue of the α-subunit. The binding of AMP to AMPK g-
subunit results in the allosteric activation of AMPK. This binding also 
makes AMPK susceptible to phosphorylation at the catalytic subunit by 
upstream kinases. Lastly, AMP binding inhibits AMPK dephosphorylation 
by protein phosphatases. AMPK activation by phosphorylation results in 
a 50 - 100 fold increase in AMPK activity, compared to a 5-fold increase 
during allosteric activation [2]. 
AMPK g-subunits have tandem pairs of the cystathionine β-synthase 
(CBS) domain (named after the enzyme cysthationine β-synthase) (figure 
1.2) [2, 10]. Each pair binds to either one AMP or ATP molecule. The 
first cystathionine β synthase pair (cystathionine β synthase 1 and 2) 
creates a binding site for AMP around arginine-70, histidine-151, 
arginine-152 and arginine-171. Mutations in Arg-70, Arg-152, and Arg-
171 results in the loss of AMP dependence, resulting in a constitutively 
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active enzyme. It has been proposed [10] that ATP binding to the CBS 
domain allows ATP to bridge the a-subunit activation site and interacts 
with molecules that interact with the phospho-threonine-172. This leads 
to the unavailability of threonine-172 for phosphorylation. Contrary to 
ATP, when AMP binds to this site the bridging of the a- and g-subunits 
does not occur and threonine-172 becomes available for 
phosphorylation. When threonine-172 is phosphorylated the bridging of 
the a- and g-subunits exposes the residue to phosphatases for 
dephosphorylation, while AMP binding to CBS shields threonine-172 
from phosphatases [10]. 
The AMPK β-subunit contains two domains named kinase interacting 
sequence (KIS) and association with SNF1 sequence (ASC). The ASC 
domain is involved in the formation of βγ-complex, while the KIS domain 
is thought to play a role in the binding of glycogen [2]. 
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Figure 1.2: AMPK isoforms and their components: the catalytic site, the 
inhibitory domain, and the subunit binding domain of α isoforms; the 
phosphorylation sites of β isoforms; the CBS domains of γ-isoforms [1].  
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1.2.2 AMPK isoform expression and their role in adaptation to    
intense physical training 
 
Winder and colleagues [11] suggested that the expression of different 
AMPK-subunits is tissue specific. In their study conducted in rats, the α
1
- 
subunit was found to be mainly expressed in slow twitch soleus and fast 
twitch red vastus lateralis muscle, whilst the α
2
-AMPK subunit was the 
main subunit in the fast twitch red and white vastus lateralis muscles, 
while its expression was low in the slow twitch soleus muscle. The β
1
- 
subunit was highly expressed in the slow twitch soleus muscle, while 
the β
2
-subunit was mainly present in the fast twitch red and white vastus 
lateralis muscles. The γ
1
-subunit was abundant in the fast twitch white 
vastus lateralis muscle and the γ
3
-subunit was mainly expressed in the 
fast twitch white vastus lateralis and slow twitch soleus muscles. 
Similarly, it was shown that γ
2
 is mainly expressed in rat fast twitch red 
vastus lateralis muscle.  
It is also important to note that the AMPK α
1
-subunit is widely 
distributed in different body tissues while the α
2
-subunit is primarily 
expressed in skeletal muscle, heart and liver. It has been suggested that 
the difference in the expression pattern of AMPK in different tissues is 
related to the energy need of the tissue concerned. For example, the 
slow twitch soleus fibers, where the a
1
 is highly expressed, have a 
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higher capacity for synthesizing ATP, and they contain many 
mitochondria and are utilized for endurance activities.  
It is also possible that the adaptation of professional athletes to intense 
physical training is mediated by AMPK. Durante et al. [12] observed that 
endurance trained rats had a reduced activation of AMPK during an 
acute bout of exercise compared to their untrained counterparts. 
Durante and colleagues [12] explained this attenuation of AMPK by a 
change in gene expression that results in a moderate degree of 
metabolic stress, this in turn leading to a more modest effect on AMP, 
ATP, and phosphocreatine levels. Note that in the cell ATP is directly 
generated from phosphocreatine [13]. The red quadriceps muscles of 
trained rats have a higher content of glycogen compared to untrained 
rats. Elevated glycogen content in muscle has been reported to greatly 
attenuate AMPK activation by muscle contraction. These findings are 
supported by a similar observation in humans where AMPK in skeletal 
muscle of trained individuals is found to be less activated during 
intense physical activities, in comparison to untrained individuals [14].  
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1.3         AMPK activators 
1.3.1         Metformin 
1.3.1.1      Biochemistry of metformin  
 
A. 
B.                     
                             
Figure 1.3: 3 dimensional structure of metformin (A). Chemical 
structure of 1,1-dimethyl biguanide or metformin (B) [15]. 
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Metformin (figure 1.3 (A) and (B)) is one of the most commonly used 
drugs for the treatment of type 2 diabetes. Although metformin has 
been in use since 1957 its exact mechanism of action remained unclear 
until recently [16]. Metformin is believed to reduce type 2 diabetes 
related mortality and the susceptibility to myocardial infarction and 
stroke, via its effects on lipid metabolism [17]. In addition to its well 
documented ability to increase glucose uptake in skeletal muscles and 
adipocytes, metformin also inhibits hepatic glucose output. Cleasby and 
colleagues [17] proposed that metformin normalizes hepatic glucose 
output by acting on key gluconeogenic enzymes, such as pyruvate 
carboxylase, pyruvate kinase, and glucose-6-phosphatase. This 
increases liver glycogen production while decreasing glucose 
production. 
One study has shown that similar to diet and exercise, metformin 
reduces the risks of developing type 2 diabetes in insulin resistant 
individuals [18]. Progression to type 2 diabetes is also prevented in 
obese individuals by the use of metformin [17]. 
Recently, there have been many studies that suggested that metformin 
acts by activating AMP–activated protein kinase [9, 19]. Musi and 
colleagues [18] showed that metformin treatment for 10 weeks 
significantly increased AMPK-a
2
 activity in skeletal muscle of type 2 
diabetic individuals. Although this study suggested that metformin can 
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change the cell energy status via alteration of the AMP/ATP ratio, 
metformin activation of AMPK is widely believed to be via activation of 
the kinase, LKB1 [20]. Nevertheless, Hawley and colleagues [21] 
suggested that the effects of metformin on AMPK is not mediated by 
any of the known AMPK kinases. Hawley and colleagues also proposed 
that metformin may be a pro-drug that is transformed intracellularly to 
its active form. Since metformin is mostly excreted in urine in an 
unaltered form, these investigators believe this hypothetical active 
species may represent only a minor fraction of the administered drug.  
Another interesting suggestion of the mechanism of metformin 
activation of AMPK came from Owen et al. [21]. This group suggested 
that metformin inhibition of complex I of the electron transport chain 
results in the lowering of the intracellular energy charge, ultimately 
resulting in AMPK activation. This hypothesis, however, was refuted by 
Hawley et al. who showed that metformin could activate AMPK even in 
cells that did not use the respiratory chain to produce ATP [21]. 
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1.3.1.2      Metformin side effects 
 
The most common side effects of metformin are weight loss and lactic 
acidosis [16, 22, 23]. The latter occurs mainly in patients with 
contraindications to the drug, such as alcoholism, renal impairment, 
severe cardiorespiratory disease, liver dysfunction and hemodynamic 
instability. It has been suggested that lactic acidosis caused by 
metformin is due to its inhibition of gluconeogenesis from alanine, 
pyruvate, and lactate, resulting in an excessive increase in plasma 
lactate concentration [18, 22]. However, Owen et al. proposed that the 
main cause of metformin induced lactic acidosis is the inhibition of 
complex I of the electron transport chain which results in pyruvate 
being converted solely to lactate, instead of also entering the citric acid 
cycle [18, 21].      
Weight loss associated with metformin is widely believed to be due to 
metformin’s action on key enzymes of lipid metabolism [23]. 
Interestingly, it has been observed that metformin can also induce 
weight loss by decreasing net caloric intake, most probably via the 
suppression of appetite [16]. 
Other side effects of metformin, although of lesser importance, include 
diarrhoea, flatulence, and abdominal discomfort. Long term use of 
metformin can also lead to vitamin B
12
 malabsorption, resulting in a 
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decrease of vitamin B
12
 intracellular concentrations and bioavailability 
[16].  
 
1.3.2           AICAR 
1.3.2.1        Biochemistry of AICAR  
 
AICAR is a nucleoside analog that enters the cell, through nucleoside 
transporters, where it is phosphorylated and converted to the 
nucleotide AICA ribotide (ZMP) by adenosine kinase. In the cell ZMP 
mimics the effects of AMP. Like metformin, AICAR stimulates glucose 
uptake in skeletal muscle by inducing the translocation of GLUT4 to the 
cytoplasmic membrane of muscle cells. The administration of AICAR in 
rats has been reported to induce a 30-40% decrease in adipose tissue 
mass [24]. However, though, widely used as an activator of AMPK, 
AICAR is not specific in its metabolic activities. AICAR also activates 
other AMP-regulated enzymes such as glycogen phosphorylase of the 
glycogenolysis pathway and fructose-1, 6-bisphosphate of the 
gluconeogenic pathway [21, 25]. A major advantage of using AICAR, in 
the study of the AMPK signaling system, is that it does not alter the 
intracellular levels of ATP, ADP, and AMP, thus any changes observed in 
AMPK activity cannot be due to the alteration of the intracellular 
(ATP)/(ADP)(AMP) ratios [26] but due to an increase in ZMP 
concentration. A study by Lochhead and colleagues [26] showed that 
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AICAR in rat hepatoma cells (4HIIE) mimics insulin by suppressing the 
gene expression of phospho-enolpyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase (G6Pase). Gene products of PEPCK and G6Pase 
are key regulators of gluconeogenesis in the liver. Defects in the 
regulation of PEPCK and G6Pase gene products have been associated 
with type 2 diabetes. PEPCK and G6Pase are found to be over expressed 
in tissues that have lost sensitivity to insulin [26]. Lochhead and 
colleagues believe that the effect of AICAR on PEPCK and G6Pase gene 
expression is through AMPK. This is consistent with the report that 
AMPK can also regulate cell energy metabolism at the level of gene 
expression [6]. This is supported by the report that constitutive 
activation of AMPK inhibits PEPCK gene expression [27]. 
AICAR is used pharmacologically, under the name acadesine, to treat 
ischemic heart disease. During ischemic stress acadesine acts as a free 
radical-scavenger, reacting with oxidants released by neutrophils. 
Acadesine is also reported to act via inhibition of adenosine deaminase, 
thus, increasing the concentration of adenosine. Adenosine plays a 
major role in the protection of body tissues during ischemia [28, 29].   
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1.4      AMP-activated protein kinase kinase. 
1.4.1     LKB1 
 
The yeast AMPK homologue, sucrose non-fermenting1 (Snf1), like AMPK, 
is activated by phosphorylation at a threonine residue of its catalytic 
subunit, the Snf1p-subunit. As shown by Hong and colleagues [30] in 
both in vitro and in vivo studies, Snf1 is phosphorylated by upstream 
kinases Pak1p, Tos3p, and Elm1p. Hong’s research group also found 
that Tos3p was able to phosphorylate mammalian AMPK. Tos3p is the 
yeast equivalent to mammalian LKB1. This enzyme is a 50 kDa 
serine/threonine protein kinase. The product of the LKB1 gene is 
mutated in the Peutz-Jeghers syndrome which is characterized by an 
increase in the risk of developing multiple tumors in various tissues 
[31]. Shaw et al. [5] demonstrated that LKB1-deficient murine embryonic 
fibroblasts have an almost complete loss of both threonine-172 
phosphorylation of AMPK and downstream signaling in response to 
AMPK activators. Investigators have also been able to show that AMPK 
activation by metformin and exercise, is achieved via LKB1[20]. 
However, a study by Suzuki et al. [32] suggested that there may also be 
a LKB1-independent pathway in the AMPK signaling system. Suzuki et 
al. observed that the phosphorylation of AMPK could also be induced by 
insulin like growth factor-1 (IGF-1). Suzuki and co-workers proposed 
that the induction of AMPK activation by this growth factor is achieved 
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via the ataxia telangiectasia mutated molecule (ATM), as any inhibition 
of this kinase expression resulted in the abolition of AMPK activation by 
IGF-1. ATM is involved in the p53 signaling system [32]. It is interesting 
to note that AMPK phosphorylation by IGF-1 could be induced even in 
LKB1-nonexpressing HeLa cells [32]. Lizcano and colleagues [33] also 
observed that phenformin, a drug closely related to metformin, 
activates AMPK via an LKB-1 independent mechanism. 
Hawley et al. [31] reported that LKB1 acts in association with other 
proteins to achieve its kinase activity. This research group showed that 
AMP-Kinase kinase (AMPKK) is a complex of proteins made up of LKB1, 
Ste20-related adaptor protein-a or -b (STRADa/STRADb) and mouse 
protein-25a or -b (MO25a/MO25b). The ability of this complex to 
activate AMPK was dependent on LKB1 activity as an AMPKK. The 
complex LKB1:STRAD:MO25 has also been shown to phosphorylate and 
activate at least 12 other kinases of the AMPK subfamily [33].  
 
1.4.2     Ca++/Calmodulin-dependent protein kinase kinase 
 
Members of the Ca++/calmodulin-dependent protein kinase kinase 
(CAMKK) family, CAMKKa and CAMKKb, show significant sequence 
homology with LKB1, Elm1p, Tos3p and Pak1p [34]. Hurley et al. [34] 
studying the AMPK signaling system in 3 cell lines deficient in LKB1 
found that mannitol, 2-deoxyglucose and ionomycin activate AMPK by 
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phosphorylation. This phosphorylation and that of enzymes 
downstream were inhibited by the CAMKK inhibitor, STO-609 and 
CAMKK siRNAs. CAMKKa is activated by Ca++, while CAMKKb is 
constitutively activated, although its activity is also stimulated by a rise 
in the Ca++ concentration.  
Leclerc and Rutter [6] showed that an increase in Ca++ concentration due 
to cell depolarization by KCl activates AMPK via CAMKK. Leclerc and 
Rutter also suggested that metabolisable amino acids such as leucine 
and glutamine may regulate AMPK activities via alteration of the 
ATP/AMP ratio as well as an increase in Ca++ influx.  
  
1.5   Cellular effects of AMPK 
1.5.1  AMPK mediates glucose transport in muscle 
 
Muscle contraction activates AMPK, and the activated kinase enhances 
glucose uptake in skeletal muscle by causing the translocation of 
glucose transporter 4 (GLUT4) to the plasma membrane [14]. However, 
it has been suggested that glucose transport induced during muscle 
contraction may not be totally controlled by AMPK. This was concluded 
after a study with α
1
- and α
2
- AMPK-subunit knock out mice, showed that 
glucose transport in the fast twitch muscle was reduced by only 40%. 
Similarly, Nielsen and colleagues [14] using transgenic mice in which 
either α
1
- or α
2
- AMPK was knocked out, found that neither the absence 
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of α
1
 nor that of α
2
 affected, in any way, glucose transport induced by 
muscle contraction. 
 
1.5.2  AMPK involvement in the nitric oxide signaling system 
 
Fryer et al. [35] suggested that glucose uptake stimulated by AMPK in 
muscle is mediated by nitric oxide synthase. They observed that AICAR 
activation of AMPK and increase of glucose transport across rat and 
mouse muscle cells was paralleled by the activation of nitric oxide 
synthase. The treatment of these cells with nitric oxide synthase 
inhibitors completely blocked the increase of glucose transport across 
the cell membrane. In the same study, an inhibitor of guanylate cyclase 
was also found to inhibit AICAR induced glucose transport across the 
cell membrane. It is, therefore, likely that AMPK increases glucose 
transport in a pathway involving nitric oxide synthase and guanylate 
cyclase. 
A study on the effects of a 30 second bicycle sprint exercise on AMPK 
activities [36], conducted on 7 males and 4 females of average age 
22±1.6 years, showed that this exercise induced the activation of both 
AMPK-a
1
 and AMPK-a
2
. AMPK activation was paralleled by a rise of about 
5,5 fold in the phosphorylation of neural nitric oxide synthase-m 
(nNOSm) at serine 145. However, this study was unable to show a direct 
association between nNOSm activation and the increase in AMPK 
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activities. The activation of nNOSm in response to intense exercise is 
believed to have a protective effect in muscle against ischemia and 
metabolic stress. Nitric oxide (NO) regulates muscle contraction, 
respiration in the mitochondria, glucose transport across the cell 
membrane, and neuromuscular transmission. Blood flow at rest and 
during recovery from exercise may also be regulated by NO [36]. 
AMPK is reported to phosphorylate and activate endothelial nitric oxide 
synthase (eNOS) in rat heart muscle in response to ischemia [36]. It is 
worth noting that ischemic conditions increase glucose uptake in the 
heart [36].  
 
1.5.3     Role of AMPK in the regulation of the sympathetic nervous 
system 
 
It is possible that AMPK plays a role in the functioning of the 
sympathetic nervous system. Viollet and colleagues [37] observed that 
AMPKα
2
-/- transgenic mice have many metabolic defects, including 
insulin resistance, while their isolated organs are metabolically normal. 
AMPKα
2
 is significantly expressed in neurons and activated astrocytes. 
The AMPKα
2
-/- mice also had high levels of catecholamine, reduced 
insulin-stimulated glucose uptake in skeletal muscle, altered glycogen 
synthesis and a considerable increase in 24 hours urinary excretion, an 
effect associated with a chronic sympathetic activation. 
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1.5.4      AMPK may regulate gene expression 
 
The activation of AMPK in pancreatic β-cells by a shift to low glucose or 
by treatment with AICAR, results in the reduction of expression of many 
important genes including glucose transporter 2 (GLUT2), aldolase B 
and liver-type pyruvate kinase (L-PK) [6]. In hepatocytes and hepatoma 
cell lines, AMPK activation by AICAR led to a decreased expression of 
fatty acid synthase (FAS), phosphoenolpyruvate carboxykinase (PEPCK), 
and glucose-6-phosphatase (G-6-pase) [6]. 
AMPK may control gene expression by directly phosphorylating 
transcription factors, transcription co-activators, or proteins involved in 
the transcriptional machinery. This assumption is supported by the fact 
that the yeast homologue of AMPK, sucrose non-fermenting 1 (Snf1), 
regulates gene expression in response to glucose availability by 
phosphorylating transcription factors. The transcription factor HNF4α is 
involved in the regulation of gene expression in the liver, intestine and 
pancreas [6]. Treatment of primary hepatocytes with AICAR resulted in a 
down-regulation of several HNF4α target genes, due to a decrease in 
HNF4α levels. AMPK may control HNF4α activity by phosphorylating it 
and enhancing its degradation [6]. AMPK is also believed to up-regulate 
the expression of transcription co-activators such as peroxisome 
proliferator-activated receptor γ coactivator 1α (PGC1a) which plays a 
role in the expression of mitochondrial genes in muscle [2]. Another 
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role of AMPK in muscle gene expression is to increase the DNA binding 
activities of muscle transcription factors nuclear respiratory factor 1 
(NRF1) and mesoderm/mensenchyme forkhead 2 (MF2). MF2 regulates 
the expression of glucose transporter 4 (GLUT4) [2]. 
The activation of AMPK was also observed to reduce the activity of RNA 
polymerase I, the polymerase that catalyses the transcription of rRNA 
[6]. AMPK regulation of gene expression can also take place at the level 
of translation. AMPK can inhibit gene translation by phosphorylating 
and activating the elongation factor-2 kinase which inhibits protein 
synthesis [2].  
 
1.5.5        AMPK inhibition of intracellular lipid accumulation  
 
A study by Habinowsky and Witters [25], conducted in mouse 
adipocytes showed a link between AMPK activation and lipid 
metabolism. Zang and colleagues [38] using metformin in hepatocytes, 
observed that AMPK activation by metformin was paralleled by a 
decrease in intracellular triacylglycerol and cholesterol.  
Villena and colleagues [39], investigating the rate of adipose tissue 
formation in AMPKa
2
 knockout mice compared to their wild type 
counterparts, found that knockout mice exhibited increased body 
weight and fat mass. This increase was caused by the enlargement of 
the pre-existing adipocytes and an increase in the rate of lipid 
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accumulation. These investigators also observed that there was no 
change in the expression of genes that control adipogenesis, such as 
CCAAT/enhancer-binding protein a (C/EBPa), peroxisome proliferator-
activated receptor g (PPAR g), and adipocyte fatty acid binding protein 
(aFABP/aP2), in the knockout mice. This suggested that the increase in 
fat deposits in these mice was not due to an increase in the rate of 
proliferation of fat cells in the absence of AMPK-a
2
, but an increase in 
the accumulation of triglyceride.  
Intracellular degradation of triglyceride is mainly achieved via the b-
adrenergic pathway, where an increase in cAMP leads to the 
phosphorylation of hormone sensitive lipase (HSL) by protein kinase A 
(PKA). The phosphorylated HSL translocates to the lipid droplet to 
initiate triglyceride degradation. A study by Yin et al. [40] showed that 
AMPK activation by the b-adrenergic agonists isoproterenol, and 
forskolin, induces lipolysis in 3T3-L1 cells. AMPK activation by these two 
agents is believed to be mediated by an increase in the intracellular 
concentration of cAMP. AMPK may also phosphorylate HSL at Ser565, a 
phosphorylation that is associated with HSL translocation to the lipid 
droplet.  
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1.6     AMPK AND TYPE 2 DIABETES MELLITUS  
 
Type 2 diabetes mellitus (T2DM) is becoming one of the leading health 
threats of the 21st century. The past few years have seen an alarming 
increase in the number of people diagnosed with diabetes throughout 
the world. Dramatic changes in our society resulting from globalization 
and industrialization, with their accompanying change in human 
behavior and life style are amongst the main causes behind the 
escalating rates of obesity and diabetes worldwide [41]. Beside 
environmental factors, the combination of heterogeneous genetic 
defects also plays an important role in determining susceptibility to 
T2DM. The close association of T2DM with genetic defects is supported 
by the fact that more than 90 % of identical twins are concordant for 
T2DM [42], and first degree relatives of diabetic persons have a 40 % 
chance of contracting T2DM compared with a 10 % chance in subjects 
with no family history of diabetes [43]. 
T2DM results from a combination of insulin resistance (reduced ability 
of insulin- sensitive tissues to respond to the binding of insulin to its 
receptor) and reduced pancreatic islet b-cell insulin secretion [44]. One 
of the major causes of insulin resistance is obesity [45]. Subjects who 
develop T2DM are those in whom the insulin output of the b-cells is not 
sufficient to counteract the insulin resistance, leading to 
hyperglycaemia and eventual b-cell secretory failure. The cause of the b-
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cell failure in T2DM is not fully understood but possible candidates 
include glucotoxity, lipotoxicity, low b-cell numbers and genetically 
programmed b-cell dysfunction [44].    
 
1.6.1     Obesity and insulin resistance  
 
Obesity is caused by an increased adipose tissue mass, resulting from 
proliferation (hyperplasia) and growth (hypertrophy) of adipocytes and 
adipocyte precursor cells [45]. The hypertrophy is due to increased 
intracellular levels of triacylglycerol (triglyceride) derived from dietary 
intake. 
Adipose tissue functions like an endocrine organ in its regulation of body 
metabolism, by secreting hormones like adiponectin [45] and leptin [46]. 
Both these hormones are activators of AMPK. Adipose tissue also plays a 
critical role of preventing lipid accumulation in other tissues which can 
result in lipotoxicity [45]. Lipid accumulation in b-cells may cause b-cell 
dysfunction whilst its accumulation in muscle may lead to insulin 
resistance [45]. Lipid accumulation in both these tissues is increased in 
obese subjects. 
Adipocytes secrete a number of factors that may affect insulin sensitivity. 
Prominent amongst these are TNFa, interleukin 6 (IL6), free fatty acids 
(FFA) and adiponectin. TNFa interferes with insulin receptor kinase activity, 
while elevated FFA may cause hyperglycemia by inhibiting skeletal muscle 
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glucose uptake or by interfering with the ability of insulin to suppress 
hepatic glucose output, as well as decreasing glucose oxidation in muscle 
[47, 48]. Adiponectin increases insulin sensitivity but serum levels of this 
hormone fall with increasing body fat mass, via an unknown mechanism 
[49]. Recently, two new adipocyte derived factors, visfatin and vaspin have 
been discovered and shown to increase insulin sensitivity [50, 51].    
 
1.6.2      The possible role of AMPK in the aetiology of type 2 
diabetes  
 
AMPK inhibition of diacyl and triacylglycerol formation may be one of 
the principal mechanisms by which AMPK activators such as metformin 
improve insulin sensitivity in skeletal muscle and other tissues [16]. 
AMPK activation inhibits the incorporation of fatty acids into 
glycerolipids, by inhibiting sn-glycerophosphate acyltransferase, an 
enzyme involved in diacylglycerol and triglyceride synthesis [52]. 
High glucose concentrations stimulate insulin secretion by the b-cells of 
the pancreas in two phases. The first phase is the release of insulin 
stored in the secretory vesicles, docked at the plasma membrane, into 
the blood stream. The second phase is the translocation of secretory 
granules from the endoplasmic reticulum to the plasma membrane of 
the cell. The movement of secretory granules is facilitated by 
microtubular motor proteins [3]. AMPK activation has been suggested to 
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inhibit the second phase of insulin secretion by phosphorylation of 
microtubular motor proteins [3]. Therefore, although AMPK actions on 
lipid metabolism may have beneficiary effects on insulin sensitivity, 
AMPK may be directly involved in the inhibition of insulin secretion in b-
cells. It is also noteworthy that metabolisable amino acids such as 
leucine and glutamine, which stimulate insulin secretion, inhibit AMPK 
[3].         
Steinberg and colleagues [53] conducted a study on the level of 
activation of AMPK and its downstream enzymes in muscle of obese and 
lean females. Their study revealed that AMPK mRNA expression, AMPK-
a
1
 and AMPK-a
2
 activities, phosphorylation of acetyl-CoA carboxylase-b 
isoform (ACC-b), and the oxidation of fatty acids were similar in both 
lean and obese subjects. Most importantly they showed that AMPK 
could be activated by AICAR to a similar degree in both groups. The 
only difference, in the two groups being that leptin did not stimulate 
fatty acid oxidation in obese subject’s skeletal muscle.  
Musi et al. [54] compared the level of AMPK activation in muscle of type 
2 diabetes and healthy subjects. They found that AMPK activation after 
20 to 45 minutes of exercise, and 30 minutes post-exercise was the 
same in both groups. Musi and colleagues observed an increase in 
AMPK activation of about 2.7 fold from basal level in the two groups 
after exercise. However, the activation of AMPK was paralleled by a 
marked decrease in blood glucose concentration, from 7.6 to 4.77 
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mmol/L in the type 2 diabetic subjects, while the blood glucose 
concentration in the control group remained the same.  
This reinforces the view that the AMPK pathway can be an attractive 
approach for improving glucose uptake in muscle of people suffering 
from type 2 diabetes or those affected by insulin resistance. Supporting 
this is the finding that AICAR increases glucose disposal in muscle and 
decreases blood glucose concentrations in animal models of diabetes 
[54]. 
The findings of Musi et al. [54] and Steinberg et al. [53] challenged 
suggestions that defects in the AMPK signaling pathway are implicated 
in the metabolic dysregulation observed in type 2 diabetes. However, 
there is growing evidence that counters this argument. Thus, AMPK 
defects have been linked with impaired insulin induced non-oxidative 
glucose metabolism, and impaired activation of glycogen synthase in 
muscle of obese subjects with type 2 diabetes [55]. Also in AMPK-a
2
 
knock out mice insulin resistance is observed and is due to effects on 
the central nervous system [55]. 
 
1.7  AMPK and HIV-1 replication 
  
Acquired immunodeficiency syndrome (AIDS) is caused by the human 
immunodeficiency virus (HIV), which progressively kills cells of the 
immune system, therefore, destroying the body’s ability to fight 
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infections and certain cancers. HIV is a member of the retroviridae 
family of virus (commonly known as retrovirus), and classified in the 
subfamily lentiviruses (slow viruses) [56]. It is widely accepted that HIV 
in humans originated from cross species transfer of a simian 
immunodeficiency virus (SIV) from chimpanzee, pan troglodytes 
troglodytes in central Africa, probably at the beginning of the 20th 
century [57]. HIV-1 and the closely related HIV-2, mostly found in West 
Africa, are believed to share a common ancestry. At the end of 2002 
about 42 million adults and children were infected with HIV [58]. In 
2002 it was estimated that 29.4 million HIV infected individuals lived in 
Sub-Saharan Africa and about 12% of the adult population in South-
Africa is infected with the virus [59]. It is estimated that about 1million 
people die every year of HIV related illnesses [60]. 
 
1.7.1 HIV-1 classification 
 
HIV-1 is classified into four groups. The first group is the group M 
(major) which is further divided into clades also known as subtypes. The 
subtypes are labeled from A to D and from F to K [58, 59]. The 
recombinant group is made of viruses that are genomic recombinants of 
different subtypes of group M [59]. The recombinant viruses are very 
common in regions were there is circulation of different HIV-1 subtypes. 
HIV-1 group O (outlier) is largely restricted to the central African region 
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[59]. Lastly, group N (non-M, non-O) has been identified in very few 
cases of HIV-1 infection in Cameroon, Gabon, and France [59]. 
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1.7.2        HIV-1 structure and life cycle 
 
 
 
Figure 1.4: Diagram depicting HIV-1 outer proteins gp120 and gp41, 
and inner proteins p9, p17, p24, p32, and p66; the viral RNA genome, 
and the outer membrane lipid in brown [61].  
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Figure 1.5: HIV-1 capsid, the structure inside the cube,  has a roughly 
icosahedral structure [61]. 
 
The human immunodeficiency virus type 1 (HIV-1) has an RNA genome 
that replicates via a DNA intermediate once the virus is inside the target 
cell. The viral RNA genome is made of two identical copies of positive 
sense RNA, which together form a single-stranded mRNA of about 9,500 
nucleotides long (figure 1.4). HIV-1 genomic RNA is found in association 
with the nucleocapsid protein p9 and p6. The viral genetic material, as 
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well as viral integrase and reverse transcriptase are contained in a 
capsid made of HIV-1 protein p24 (figures 1.4 and 1.5). The capsid is 
coated with a layer of matrix protein p17, which in turn is associated 
with the outer lipid layer, or viral envelope, acquired from an infected 
cell. Out of the viral envelope protrude gp120 and gp41 proteins, which 
help the virus attach to the host cell receptors during infection (figure 
1.6 (A) and (B)) [62].  
In the host cell HIV-1 reverse transcriptase synthesizes a double-
stranded DNA version of its RNA genome. The DNA is then integrated, 
as a provirus, into the host cell genome. The provirus becomes part of 
the host cell DNA and it is replicated along with it, every time the cell 
divides. Two identical structures, the long terminal repeat (LTR), are 
generated at each end of the provirus, in the course of the reverse 
transcription of the HIV-1 genomic RNA. During the course of an HIV 
infection the transcription of the integrated provirus begins with the 
activation of enhancer and promoter sequences in the LTR (figure 1.7) 
[63]. 
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A.                                                              
  
 
B.               
 
Figure 1.6: (A)  and (B) Show the interaction of HIV-1 gp120 and gp41 
with the host cell receptor CD4 and co-receptor CCR5 [62]. 
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Figure 1.7: Diagrammatic representation of HIV-1 life cycle [61]. 
 
1.7.3     HIV-1 infectivity 
 
Many cellular factors can promote HIV-1 replication in a latently infected 
cell i.e. in an infected cell that does not produce viral particles. These 
factors may include antigens which can stimulate the differentiation of 
infected cells, therefore, stimulating the integrated provirus to replicate. 
The infection of the host cell by other viruses such as the herpes 
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simplex virus or the cytomegalovirus may also result in the initiation of 
viral replication [58]. HIV-1 transcription results in the production of 
infective virions that will bud from the host cell into the blood stream to 
infect other target cells. HIV-1 targets cells carrying the CD4 cell surface 
antigen and the chemokine receptors CCR5 and CXCR4 are also 
required for a successful infection (figure 1.6 (A) and (B)) [64]. HIV-1 
infects mainly T-cells (figure 1.8), monocytes, macrophages, and 
dendritic cells. However, except for T-cells, the other cells are generally 
not destroyed by HIV-1; they act as a viral reservoir in an infected 
individual [7].  
 
 
Figure 1.8: A photograph of HIV, in blue, budding from a T-cell [65]. 
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1.7.4      HIV-1 genome 
 
The HIV-1 genome contains 9 genes [57]. The env encodes the viral 
protein gp160 the precursor protein of gp120 and gp41; the gag gene 
product is the precursor polyprotein Pr55 which is cut by HIV-1 protease 
to make 4 small internal structural proteins [66]. The role of Nef is still 
uncertain; however, it is believed that it may play a role in the infection 
of the host cell. Pol encodes the polyprotein Pr160, the precursor of HIV 
protease and reverse transcriptase [66]. Rev encodes HIV-1 Rev protein 
which plays the role of transferring viral RNA from the nucleus into the 
cytoplasm [67]. Tat encodes Tat which increases the rate of expression 
of HIV-1 genes [68]. Vif increases HIV-1 infectivity; vpr encodes 
transcriptional activators and vpu participates in viral assembly and 
budding [66].     
 
1.7.5       Nuclear factor-κB and HIV-1 replication 
                            
The NF-κB proteins are a large family of inducible nuclear factors 
responsible for controlling gene expression after injury or during the 
inflammatory response [69]. Proteins of this family share a conserved 
300 amino acid region called Rel homology domain (RHD), responsible 
for DNA binding and dimerization. So far eight members of the NF-κB 
family have been identified: NF-kB1 (p50/p105), NF-kB2 (p52/p100), 
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cRel, RelA (p65), RelB and the drosophila proteins Dorsal, Dif and Relish. 
P50 and p52 are generated by proteolytic processing of p105 and p100, 
respectively [69, 70]. The most abundant member of the family, 
however, is a heterodimer made of subunit p50 and p65 (figure 1.9). 
P65 contains a powerful transcriptional activation domain. NF-κB dimers 
are found in their inactive form in the cytoplasm where they are bound 
to one of 3 inhibitor IκB isoforms (IkBa, IkBb, and IkBe) [71]. 
Physiological factors, such as interleukin-1 and tumor neucrosis factor 
(TNF)-a, can induce the phosphorylation of IκB by IκB kinase (IKK)b. The 
phosphorylated IκB is ubiquitinylated and degraded by the 26S 
proteasome. This releases NF-κB allowing it to migrate to the nucleus to 
bind to DNA and initiate gene transcription (figure 1.10). 
In addition to the classical NF-κB cascade, another pathway to generate 
a different NF-κB complex (RelB attached to p100) has been proposed. 
This pathway involves IKKa, a subunit of the IKK complex, rather than 
IKKb. IKKa phosphorylates p100, in the cytoplasm, and this triggers 
processing of p100 to p52. The activated RelB-p52 complex then 
migrates to the nucleus to induce gene transcription [70].  
Phosphorylation is extensively involved in the metabolic control of NF-κB 
activities i.e. its transport to the nucleus, processing of its precursors, 
stabilization of its dimeric form, and its binding to DNA. In the nucleus 
phosphorylation of p65 by mitogen- and stress-activated protein kinase-
1 (MSK-1) at residue Ser276 of the RHD region, in response to TNF-a, 
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induces NF-κB-dependent gene transcription. P65 is also phosphorylated 
by protein kinase A (PKA) [70] leading to increased transcription of NF-
kB responsive genes.  
It is possible that NF-κB induces gene transcription by combining with 
other nuclear proteins, such as CBP/p300, via the p65 subunit. Mutation 
at Ser276 blocks NF-κB binding to CBP/p300 and results in the loss of 
NF-κB induced gene transcription [69].  
 
 
 
Figure 1.9: Chemical model of the most abundant member of the NF-kB 
family [72].  
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Figure 1.10: IkB phosphorylation and degradation followed by NF-kB 
release and migration to the nucleus, where it initiates gene 
transcription [72].    
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1.7.6       NF-κB cooperates with the viral protein Tat to initiate HIV-1 
replication 
 
The replication of HIV-1 in T-lymphocytes is modulated by the viral 
proteins Tat, Rev and Nef. Tat and Rev bind to the viral RNA transcript, 
and are essential for gene expression at the transcriptional and 
posttranscriptional levels. In addition to these proteins, there is a strong 
requirement for host cell factors before HIV-1 replication begins [63]. 
The long terminal repeat in the viral genome regulates gene expression. 
HIV-1 LTR is divided into three main regions: modulator, core and TAR. 
The modulator region contains numerous cis-acting sequences for the 
binding of transcriptional factors such as NF-κB, NF-AT and AP-1. These 
cis-acting sequences have two highly conserved copies of the κB 
elements. The activation of the κB element is achieved by the binding of 
an activated NF- κB.  
Cheng et al. [63] studying the activation of the HIV-1 genome by the 
human T-cell leukemia virus type-1 Tax protein showed that the 
activation of HIV-1 LTR by Tax is achieved through cooperation of this 
protein with HIV-1 Tat. Most importantly, they observed that the 
activation of a mutant strain of HIV-1 that had a deletion in the κB 
element was reduced about 145-fold compared to the wild type. Using 
nuclear factor activators such as phorbol myristate acetate (PMA) for NF-
κB and phytohemagglutinin (PHA) for NF-AT, these investigators came to 
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the conclusion that NF-κB was required for full activity of the HIV-1 LTR 
and that this nuclear factor was critical for Tat responsiveness, 
especially during the early postintegration stage of HIV-1 infection [63]. 
The same study also showed that the HIV-1 Nef protein activates viral 
replication in association with tat and NF-κB. It is worth noting that a 
latent viral infection is in part maintained by the lack of cellular 
transcription factors, needed for the induction of HIV early regulatory 
genes [7]. Herpex simplex virus infection of HIV-1 infected cells, as well, 
appears to activate HIV-1 LTR expression partly through the activation 
of NF-kB binding activities [73]. 
 
1.7.7        NF-κB cis-acting motifs regulate HIV-1 transcription in 
human macrophages 
 
Macrophages play an important role during the sexual transmission of 
HIV-1, as this mode of transmission involves mucosal tissues where 
macrophages are amongst the first cells to be exposed to the virus.  
At the early stages of an HIV-1 infection the viral strains found in the 
system are macrophage tropic and T-lymphocyte tropic viruses emerge 
progressively as the diseases progresses [64].  
Macrophages contain a constitutive nuclear pool of NF-κB and in 
contrast to T-cells this pool allows for a basal level of HIV-1 
transcription and replication in the absence of cell stimulation. The 
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ability of HIV-1 to infect and replicate in macrophages is critical to the 
pathogenesis of AIDS. Macrophages behave like major viral reservoirs, 
facilitating persistent HIV-1 replication and infection of target cells via 
cell to cell contact, hence, accelerating the progression to AIDS [7]. Asin 
and colleagues [7] investigating the role of the nuclear pool of NF-κB in 
HIV-1 transcription, observed that its inhibition with a dominant NF-κB 
inhibitor, IκB α, led to a significant reduction of HIV-1 replication in the 
promonocytic U937 cell line. The reduction of this pool in human 
macrophages by an adenovirus vector expressing a dominant negative 
IκB α also gave the same result [7]. 
A study by Paya et al. [74] showed that HIV-1 infected U937 cells, had 
an increased accumulation of NF-κB (p50/p65) in their cytoplasm when 
compared to uninfected U937 cells. It is believed that HIV-1 infection of 
U937 results in a continuous translocation of NF-κB (p50/p65) to the 
nucleus. The translocated NF-κB up-regulates the gene expression of 
p105, precursor of p50. This in turn causes p50/p65 NF-κB 
accumulation in the cytoplasm. The observation that HIV-1 may 
perpetuate its own gene transcription in monocytes may explain why 
macrophages play the role of viral reservoirs during an HIV-1 infection.   
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1.7.8 TNF-α initiate HIV-1 replication via NF-κB 
 
Duh et al. [73] using a chronically infected T-cell line (ACH 2), observed 
that its treatment with TNF-α results in an increase in the steady-state 
level of HIV-1 RNA and HIV-1 transcription. They observed a 4- to 5- fold 
increase in steady-state HIV-1 RNA and a 3- fold increase in HIV-1 
transcription. This occurred through a transcriptional activation of the 
HIV-1 long terminal repeat (LTR) and binding of a nuclear factor to the 
NF-κB sites. It is interesting to note that there is an increase in the 
plasma level of TNF-α in AIDS patients compared to asymptomatic HIV-
seropositive individuals [73] . 
 
1.7.9     AMPK inhibition of transcriptional activators used by HIV-1 
 
It can be concluded that NF-κB (p50/p65) is a key nuclear factor that 
promotes HIV-1 gene expression. Interestingly, AMPK activation by 
AICAR suppresses NF-κB mediated gene expression [1]. Similarly, 
adiponectin, an abundant adipocyte-derived plasma protein and a well 
known activator of AMPK, inhibits TNF-a induced expression of 
adhesion molecules on cultured endothelial cells. This is caused by 
adiponectin inhibition of TNF-a mediated phosphorylation of inhibitor-
kB (I-kB), leading to inactivation of NF-kB [75].   
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AMPK has also been reported to phosphorylate the transcriptional co-
activator p300 and CBP. The phosphorylation of p300 inhibits its 
interaction with nuclear receptors, while CBP phosphorylation blocks its 
binding to DNA [1]. As shown by Marzio et al. [76] p300 and CBP, which 
have histone acyltransferase activities and are required for the initiation 
of HIV-1 replication, are recruited by HIV-1 tat at the viral LTR before the 
initiation of gene transcription. Also as said earlier NF-kB p65 interacts 
with p300/CBP during gene transcription [69].  
 
1.7.10     HIV treatment 
 
The first anti-retroviral approved for use against HIV is zidovudine, also 
known as AZT. This drug was first developed as an anti-cancer; 
however, in late 1980s it became known that AZT also had anti-
retroviral activities [77]. AZT is a nucleoside analogue reverse 
transcriptase inhibitor (NRTI), it inhibits HIV reverse transcriptase [77]. 
Besides AZT other NRTI such as didanosine and zalcitabine are also 
used against HIV [77]. HIV infection can also be treated with Non-
nucleoside analogue reverse transcriptase inhibitors (NNRTI) such as 
efavirenz and protease inhibitors (PI) such as indicavir [77]. However, 
the most effective treatment of HIV infection is the highly active anti-
retroviral therapy (HAART). This treatment combines at least 3 anti-
retroviral drugs in a single regimen. 
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Long term HAART have been associated with severe side effects 
amongst which are lipodystrophy, insulin resistance and type 2 
diabetes, cumulative mitochondrial damage, and lactic acidosis [77]. 
The treatment of HIV infection with single NRTI, NNRTI, or PI has also 
been associated with toxic effects ranging from mild to life threatening 
[77].   
                  
1.8        Aims of the study 
 
Metformin is known to cause weight loss. Metformin and AICAR can 
activate AMPK, and AMPK activation in pre-adipocytes causes an 
inhibition of adipogenesis. Therefore, the first aim of this study was to 
investigate whether metformin may inhibit adipogenesis in the murine 
pre-adipocytes cell line 3T3-L1. The second objective was to study 
metformin and AICAR activation of AMPK and to determine if this 
inhibits HIV-1 replication in chronically infected U1-cells, by inhibiting 
NF-kB expression. 
 
 
 
 
 
 
 
 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
                             CHAPTER 2 
                    MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 48 
2.1   AMPK inhibition of adipogenesis 
2.1.1 Optimization of AICAR and metformin concentration for 
adipogenesis 
 
The optimization experiment was performed with 0.5 mM, 0.75 mM, 
and 1 mM AICAR (see appendix II for the preparation of AICAR stock 
solution). The choice to use 1 mM as the highest concentration of AICAR 
in the titration curve was based on Hawbinosky and Witters study [25] 
on AICAR inhibition of adipogenesis in 3T3-L1, mouse pre-adipocytes 
that can be transformed into adipocytes. In this study the inhibition of 
adipocyte differentiation was the highest in cells cultured with 1mM 
AICAR.  
The optimization experiment for metformin began with 2 mM (see 
appendix II for the preparation of metformin stock solution). The other 
two concentrations used were 3 mM and 4 mM. The choice to begin the 
titration curve with 2 mM was based on a Zhou et al. study [9] that used 
the same concentration of metformin to inhibit intracellular lipid 
accumulation in hepatocytes. 
The method used for the optimization experiment was as follows: 
1. The 3T3-L1 cell line (appendix I) was cultured in DMEM 
maintenance medium (appendix II) in a 25 cm2 flask, at 37 °C in a 
humidified atmosphere containing 5 % CO
2
.  
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2. At confluence cells were trypsinized (section 2.1.4) and a 0.5 mL 
aliquot was transferred to eight 25 cm2 flasks.  
3. These cells were cultured to confluence.  
4. At confluence (day 0) one tissue culture was stained with Oil red 
O [78] for baseline lipid content.  
5. For the remaining seven flasks (on day 0): one culture was left 
untreated (the negative control), three were treated with different 
concentrations of metformin, 2 mM, 3 mM, and 4 mM; and three 
others were treated with 0.5 mM, 0.75 mM, and 1 mM AICAR and 
cell transformation (adipogenesis) was induced in these seven 
tissue cultures by treating the cells in 5 mL of maintenance 
medium with 5 x 10-4 M 3-isobutyl-1-methylxantine (IBMX), 2.4 x 
10-7 M dexamethasone and 0.28 U/mL insulin (see appendix II for 
the preparation of IBMX and dexamethasone stock solutions).  
6. On day three the medium was changed to maintenance medium 
plus insulin only.  
7. On day six the culture medium was replaced with maintenance 
medium without IBMX, dexamethasone, or insulin, until day eight. 
8. On day eight all the cultures were stained with Oil red O (section 
2.1.6).  
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2.1.2     3T3-L1 cell culture, treatment with AICAR and metformin, 
and initiation of adipogenesis  
 
The initiation of adipogenesis of cells treated with AICAR and 
metformin was carried out as described in section 2.1.1. In this 
experiment cells were treated with 2 mM, 4 mM, 8 mM, and 16 mM 
of metformin. Cells treated with 1mM of AICAR were used as positive 
control, as AICAR is a well known inhibitor of adipogenesis [25]. 
 
2.1.3    Detection of AMPK phosphorylation by AICAR and metformin 
 
1. 3T3-L1 cells were cultured in a 25 cm2 flask as in section 2.1.1.  
2. At confluence cells were trypsinized and a 0.5 mL aliquot was 
transferred to four 25 cm2 flasks.  
3. Cells were again cultured until confluent.  
4. At confluence, total cytoplasmic protein was extracted from one 
culture (section 2.1.7), for Western blotting to quantify the 
baseline phosphorylation of AMPK (section 2.3).  
5. For the remaining three flasks: one culture was left untreated, one 
culture was treated with 16 mM metformin; and the last cell 
culture was treated with 1mM of AICAR and cell transformation 
was induced in these three cultures using the method described 
in section 2.1.1. 
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6. After three days the medium was changed to maintenance 
medium plus insulin only.  
7. On day six the culture medium was replaced with a maintenance 
medium without IBMX, dexamethasone, or insulin, until day eight. 
8. On day eight total cytoplasmic protein was extracted from all the 
cultures, and Western blotting was performed (section 2.3), to 
measure the phosphorylation of AMPK by AICAR and metformin. 
This experiment was repeated five times.  
 
2.1.4     3T3-L1 trypsinization 
 
1. Confluent 3T3-L1 cells in a 25 cm2 flask were trypsinized by 
washing the cells twice with phosphate-buffered saline (PBS) 
(appendix II), 5 mL for the first wash and 1 mL for the second.  
2. PBS was pipetted out of the flask and the cells were left in 1 mL 
trypsin for 10 to 15 minutes at 37 ºC.  
3. The trypsinization reaction was stopped by adding 4 mL of 
maintenance medium into the flask.  
4. Suspended cells were then transferred to the relevant number of 
fresh flasks, containing maintenance medium, for tissue culture.   
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2.1.5       Oil red O preparation 
 
1. Oil red O (105 mg) was dissolved in 30 mL of absolute isopropyl 
alcohol. The solution was stirred overnight on a magnetic stirrer, 
at room temperature.  
2. The following day the solution was filtered thrice through a 
Whatman paper filter, and 22.5 mL of bidistilled water was added 
to the solution.  
3. The solution was left at 4 ºC overnight, for use the following day. 
 
2.1.6     Oil red O staining  
 
When 3T3-L1 cells are stained with Oil red O, the dye enters the cells 
and binds to intracellular lipid. Therefore, the higher the concentration 
of lipid inside the cell, the higher the amount of dye that binds to them. 
The dye is then extracted with 60 % (v/v) isopropyl alcohol in water and 
the absorbance readings of the dye-isopropyl alcohol solution is taken 
at 510 nm. The optical density is, therefore, proportional to the 
intracellular lipid concentration.  
The method used was as follows: 
1. 3T3-L1 cells in a 25 cm2 flask were fixed with 2 mL of 3 % (v/v) 
gluteraldehyde in water for 2 hours. 
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2. The gluteraldehyde solution was poured out and replaced with 
2.5 mL of 60 % (v/v) isopropyl alcohol. 
3. After 5 minutes the 60 % isopropyl alcohol was removed from the 
flask, and the flask was left with its cap removed for ten minutes, 
to allow for residual isopropyl alcohol to evaporate.  
4. The cells were stained with 1.5 mL Oil red O for 2 hours. 
5. The dye was removed from the flask and the cells were rinsed 
with 2.5 mL of 60 % (v/v) isopropyl alcohol for 5 seconds. 
6. The dye was extracted by adding 3.5 mL of 60 % (v/v) isopropyl 
alcohol and leaving the flask on an electric shaker for 2 hours.  
7. The optical density of the extracted dye was read at 510 nm.    
 
2.1.7       Protein extraction from 3T3-L1 
 
1. Adherent 3T3-L1 cells were removed from culture flasks by 
treatment with trypsin.  
2. The cells were pelleted by centrifugation at 670 xg for 10 minutes 
and resuspended in 5mL of warm Krebs-HEPES buffer (appendix 
II). The resuspended cells were left in the incubator for 30 
minutes at 37°C.  
3. Cells were again centrifuged at 670 xg for 10 minutes and the 
resulting pellet was kept on ice while 0.8 mL of ice-cold lysis 
buffer (appendix II) was added to it. 
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4.  The cell lysate was centrifuged at 18,000 xg at 4 ºC for 3 
minutes and the resulting supernatant retained for Western 
blotting. 
5. The protein concentration was determined using the Bradford 
method (section 2.1.8). 
 
2.1.8      Determination of protein concentration using the Bradford 
Method 
 
Required: 
Coomassie reagent (appendix II), 
albumin at a concentration of 1 mg/mL for standard curve [79]. 
 
The standard curve was prepared as follows: 
Stock Albumin (mL) H
2
O  Concentration (mg/mL) 
0    1000  0 (blank) 
20    980  20 
40    960  40 
60    940  60 
80    920  80 
100    900  100 
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Method 
 
1. Duplicate 5 mL tubes were labeled according to standards and 
samples. 
2. 300 mL standard/sample and 2.7 mL of coomassie reagent were 
added to each tube. 
3. The sample and reagent were mixed and the absorbance reading 
was taken at 595 nm on a spectrophotometer. 
Notes: Lysates from 106 cells should be diluted 1:20 as a starting point 
to fall within the standard curve. 
 
2.2   AICAR and metformin inhibition of HIV-1 replication 
in U1 cells 
2.2.1    Optimization of AICAR and metformin concentration for HIV-
1 inhibition in U1 cells 
 
Because this study was carried out after the adipogenesis study, the 
choice of AICAR and metformin concentrations to use against HIV-1 was 
guided by the concentrations used in the adipogenesis study i.e. for 
metformin we used the same concentrations we used in the 
adipogenesis study, except 2 mM, and for AICAR we used 
concentrations ranging from 0 to 1 mM.  
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The concentration of AICAR and metformin was optimized by using the 
following method:  
1. U1 cells, HIV-1-chronically infected monocytes  [80, 81], were 
cultured in suspension in a 75 cm2 flask. The cells were grown in 
RPMI 1640 containing 10 % foetal calf serum, at 37 °C in a 
humidified atmosphere containing 5 % CO
2
.  
2. After 72 hours, viable cells were counted under an inverted light 
microscope using trypan blue exclusion. Viable cells stained light 
blue and non-viable cells stained dark blue. A 1x106 cells/mL 
solution was prepared in RPMI 1640, supplemented with 10 % 
foetal calf serum.  
3.  A 0.5 mL aliquot was transferred into nine wells of a 24-well 
plate and cells were treated with 4 mM, 8 mM, and 16 mM 
metformin (the concentration of metformin stock solution is given 
in appendix II), in triplicate. In another 24 well plate U1 cells were 
treated with 0.1mM, 0.2mM, 0.35mM, 0.4mM, 0.5mM, and 1mM 
of AICAR (the concentration of AICAR stock solution is given in 
appendix II), also in triplicate. In six wells of a third 24-well plate 
was transferred 0.5mL of the cell suspension. These remaining 6 
wells remained untreated, these cells will be referred to as 
untreated cells.                         
4. The cell cultures were incubated for 1 hour at 37 ºC to allow 
metformin and AICAR to activate AMPK.  
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5. HIV-1 replication was activated by the addition of NaCl to a final 
concentration of 60 mM [80] (the concentration of NaCl stock 
solution is given in appendix II) to metformin and AICAR treated 
wells, including three of the six untreated wells. Three untreated 
wells were used as the positive controls, and three untreated 
wells remained without AICAR, metformin, and NaCl and were 
used for background measurement of p24, HIV-1 core protein, in 
U1 cells.  
6. After 48 hours, U1 cells in all the wells were counted using an 
inverted light microscope and HIV-1 replication was measured by 
measuring the p24 antigen concentration [80], of each culture, by 
ELISA. The p24 ELISA was performed on the supernatant from 
each well, according to the manufacturer’s instructions (Dupont, 
Boston, MA) (section 2.2.3).  
 
2.2.2    U1 cell culture and treatment with AICAR and metformin 
 
This experiment was carried out the same as in section 2.2.1. However, 
the concentrations of AICAR used here were 0.2 mM, 0.35 mM, and 0.4 
mM. Cells treated with 0.4 mM AICAR, 16 mM metformin, and cells 
treated with NaCl only, were used for the extraction of total nuclear and 
total cytoplasmic protein (section 2.2.4).  
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Western blotting (section 2.3) was performed with these protein 
extracts to quantify the cytoplasmic and nuclear concentrations of NF-
κB. The protein extracts were also used for the AMPK α subunit and 
phospho-AMPK α subunit Western blotting.  
 
2.2.3      HIV-1 P24 antigen ELISA 
 
The p24 ELISA uses a 96-well plate coated with anti-HIV-1 p24 antibody. 
HIV-1 replication results in the budding of the virus from the infected 
cell into the culture supernatant [82]. The amount of p24, after lysing 
the virus with Triton X 100®, captured on the plate is proportional to 
the rate of HIV-1 replication in the cells [80]. 
The rows of the plate were labeled from A to H, and the columns were 
labeled from 1 to 12.  
 
The protocol was the following: 
1. Serial dilutions for the standard curve were made, with the p24 
antigen (provided), using row A to F of column 1, as follows: 
A = 10.0 ng/mL of p24    (190 μL of 0.5% Triton-X 100 + 10 μL of p24 
solution). 
B = 2.5 ng/mL of p24       (150 μL of 0.5% Triton-X 100 + 50 μL of A). 
C = 0.625 ng/mL              (150 μL of 0.5% Triton-X 100+ 50 μL of B). 
D = 0.156 ng/mL              (150 μL of 0.5% Triton-X 100+ 50 μL of C). 
   D.   C.   B.    A. 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
6. 
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E = 0.04 ng/mL                 (150 μL of 0.5% Triton-X 100+ 50 μL of D). 
F = 0.01ng/mL                 (150 μL of 0.5% Triton-X 100+ 50 μL of E). 
Well G of column 1 was used as the blank for background reading. 
2. 100 μL of the sample was added to the ELISA plate. Note that the 
sample is 25 μL of the U1 cell culture supernatant plus 225 μL of 
0.5% Triton-X 100. 
After adding the sample to the plate, the plate was sealed and 
incubated for 1 hour at 37 ºC. After the incubation the plate was 
washed 6 times and dried. All reagents, including the wash buffer, were 
supplied with the kit.  
3. A 100 μL aliquot of the detector antibody was added to all the 
wells except the blank. The plate was sealed and incubated for 1 hour 
at 37 ºC. After the incubation the plate was washed 6 times and dried. 
4. Streptavidin-HRP (horse radish peroxidase) was diluted 1:100 with 
Streptavidine-HRP diluent and 100 μL of the streptavidine-HRP solution 
was added to all the wells except the blank. The plate was sealed and 
incubated at room temperature for 30 minutes, then washed 6 times 
and dried. 
5. OPD: 1 tablet/11mL of substrate diluent was prepared and 100 μL 
of this solution added to all wells, including the blank.  
6. Kinetic curve setting was used to read the optical density (OD). 
From these values taken in a given interval of time i.e. the rate of 
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conversion of the substrate, the p24 concentration in different wells 
was calculated by the computer connected to the plate reader. 
Note that all the concentration readings were multiplied by 10 as the 
samples were diluted 10 times (25 μL of the U1 cell culture supernatant 
plus 225 μL of 0.5% Triton-X 100). 
 
2.2.4   U1 cell protein extraction 
 
The Nucbuster protein extraction kit (appendix I) was used according to 
the manufacturer’s instructions: 
All extractions were performed on ice to enhance protein stability.  
1. U1 cells were pelleted in a 1.5 mL Eppendorf tube by 
centrifugation at 500 xg at 4 ºC. The supernatant was removed 
and 150 µL of Nucbuster reagent 1 was added to the pellet. 
2. The tube was vortexed for 15 seconds at high speed, incubated 
on ice for 5 minutes and again vortexed for 15 seconds at high 
speed. 
3. The tube was centrifuged at 16,000 xg for 5 minutes at 4 ºC. 
4. The supernatant (cytoplasmic fraction) was stored at -20 ºC. 
5. The pellet was resuspended in a solution of 1 µL of resuspended 
100 X inhibitor cocktail, 1 µL of 100 mM DDT, and 75 µL 
NucBuster extraction reagent 2.  
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6. The pellet was vortexed for 15 seconds at high speed, incubated 
on ice for 5 minutes and again vortexed at high speed for 15 
seconds. 
7. The pellet was centrifuged at 16,000 xg for 5 minutes. 
8. The supernatant (nuclear extract) was transferred to a separate 
tube and stored at -80 ºC.  
Protein concentration was determined using the Bradford method as 
described previously (section 2.1.8). 
 
2.3      Western blotting 
2.3.1   Protein electrophoresis  
 
1. One part of the reducing solution with loading dye (appendix II) 
was mixed with 4 parts of the sample in a 1.5 mL Eppendorf tube.  
2. The cap of the Eppendorf tube was pierced with a needle, and the 
tube was placed in a heating block at 70 °C for 5 minutes.  
3. The heated solution was cooled and 4 mg of each protein extract 
was loaded onto a sodium dodecyl sulfate PAGE gel (appendix II).  
4. The gel was run for 2 hours at 120 V (constant voltage) and a 
current of 63 mA. 
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2.3.2      Protein transfer to the Immobulon-P membrane 
 
1. The gel was removed from its glass cassette, and the stacking gel 
was trimmed away.  
2. The gel was equilibrated in the transfer buffer (appendix II) for 15 
to 30 minutes.  
3. Two Biorad trans-blot filter papers were soaked in the transfer 
buffer for at least 30 seconds. Four packing sponges of the same 
size as the filter papers and of about 3 mm thickness were 
soaked in the transfer buffer for at least 2 minutes. An 
Immobulon-P membrane (appendix I) was soaked in methanol for 
15 seconds (The membrane should uniformly change from 
opaque to semi-transparent when soaked in methanol). The 
membrane was then carefully placed in ultra-pure water (milli-Q 
water) and soaked for 2 minutes. Finally the membrane was 
placed in the transfer buffer and equilibrated for at least 5 
minutes. 
4. A pre-soaked packing sponge was placed in the centre of the 
cathode half of a cassette holder.  
5. A piece of wet filter paper was placed on the sponge. The 
equilibrated gel was placed on the filter paper.  
6. The immobulon-P membrane was put on the gel. The membrane 
should not be re-positioned once it contacts the gel.  
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7. One piece of wet filter paper was placed on the membrane, and 
two or more packing sponges were put on top of the filter paper. 
8. The cassette holder was closed and placed in the transfer tank. 
9. The transfer buffer was poured into the cassette holder until it 
covered the cassette.  
10. Cold distilled water was poured into the transfer tank, to absorb 
the heat released by the current used for protein transfer. The 
transfer was carried out using a constant current of 250 mA for 1 
hour. 
 
2.3.3   Drying the membrane after protein transfer 
 
After the protein transfer, the membrane was dried by soaking it in 100 
% methanol for 10 seconds, and by leaving it on a piece of filter paper 
at room temperature for approximately 15 minutes, until dry. 
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2.3.4    Rapid chemiluminescent detection of proteins on the  
Immobulon-P membrane 
 
Rapid immunodetection takes advantage of the fact that antibodies 
cannot bind to the hydrophobic surface of the Immobulon-P membrane, 
but will bind to a protein immobilized on the membrane. With this 
detection method, blocking of the membrane is not required. Excess 
antibody cannot bind to a dry membrane and therefore reduces the 
amount of washing.  
The membrane should be thoroughly dry for the detection to be 
successful. 
1. The primary antibody (anti-phospho-AMPK α
2
 subunit, anti-AMPK 
α
2
 subunit, or anti-NF-κB antibody) was prepared in 1% milk tris-
buffered saline-tween20 (TBS-T) (0.1 % tween) (appendix II). The 
primary antibodies were diluted as follows: anti-phospho-AMPK α
2
 
1/1000, anti-AMPK α
2
 1/1000, anti-NF-κB 1/500. 
2. The blot was placed in primary antibody solution and incubated 
with agitation for 1 hour. 
3. The blot was rinsed quickly with TBS-T, and placed again in TBS-T 
and washed for 5 minutes. The washing was repeated twice with 
fresh buffer. 
4. The blot was placed in the horse radish peroxidase (HRP)-
conjugated secondary antibody solution, in 1 % milk TBS-T, and 
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incubated with agitation for 30 minutes. Note that the anti-
phospho-AMPK α
2
 and the anti-NF-κB were raised in rabbit; 
therefore, the secondary antibody used for their detection was a 
goat anti-rabbit antibody diluted 1/2000. Anti-AMPK α
2
 was raised 
in sheep; hence, the secondary antibody used for its detection 
was a rabbit anti-sheep diluted 1/1000.  
5. The blot was rinsed quickly with TBS-T, and placed again in TBS-T 
and washed for 5 minutes. The washing was repeated twice with 
fresh buffer.  
6. The substrate for enhanced chemiluminescent (ECL) (appendix I) 
detection was prepared by mixing an equal volume of ECL 
detection reagent solution 1 and ECL detection reagent solution 
2. 
7. The blot was placed in a container; a sufficient amount of the 
substrate was added to cover the entire surface of the membrane; 
and incubated for 1 minute. 
8. The excess substrate was drained with a piece of paper towel. 
9. The blot was placed on a clean piece of plastic wrap, protein side 
down, and wrapped. 
10. Air bubbles, between the membrane and the plastic wrap, were 
removed by gently passing a finger across the surface of the 
plastic wrap.  
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11. In the dark room the wrapped membrane was placed, protein side 
up, in a film cassette. 
12. A sheet of auto-radiography film was placed on top of the 
membrane and the cassette was closed. 
13. The film was exposed; for the optimal detection of phospho-
AMPK the film was exposed overnight. The optimal detection of 
non-phosphorylated AMPK required 2 to 3 minutes of exposure. 
The optimal detection of both cytoplasmic and nuclear NF-κB also 
required 2 to 3 minutes of exposure. 
14. Protein band intensity was quantified using the Kodak 1D Image 
Analysis Software v3.6. 
 
2.3.5   Amido black staining 
 
Amido black staining was performed after each ECL detection 
experiment for the cytoplasmic and nuclear NF-κB of U1 cells. This was 
to verify whether the observed difference in the cytoplasmic and nuclear 
concentrations of NF-κB, between metformin and AICAR treated cells 
and the control cells, was due to the effects of AICAR and metformin, 
and not due to unequal amounts of protein loaded in the wells. Amido 
black is a non-reversible stain that produces dark bands on a light back-
ground.  
Required reagents: 
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Amido black stain (appendix II),  
destain solution (appendix II), 
100 % methanol, 
ultra-pure water. 
1. A dry blot was first re-wetted in 100 % methanol for 15 seconds.  
2. A tray was filled with enough stain to cover the blot and the blot 
was placed in the stain and agitated for 10 minutes.  
3. The blot was removed and rinsed briefly in ultra-pure water.  
4. The blot was then placed in destain solution and agitated for 5 to 
10 minutes to remove excess stain.  
 
2.3.6       Statistical analysis 
 
 
The Wilcoxson matched pairs test, using Statview, was used for all 
statistical calculations. The difference between means with a p-value of 
≤ 0.05 was considered to be statistically significant. Data in histograms 
is expressed as mean ± SD. 
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3.1     3T3-L1 Results 
3.1.1    Optimization of AICAR and metformin concentration for 
adipogenesis 
 
3T3-L1 were cultured in the presence of three different concentrations 
of AICAR 0.5 mM, 0.75 mM, and 1 mM; and three different 
concentrations of metformin 2 mM, 3 mM, and 4 mM. AICAR at the 
concentration of 1 mM had the highest inhibition of adipogenesis. 
Therefore, 1 mM AICAR was used as the adipogenesis inhibition control 
(positive control) in all the subsequent experiments.  
Among the three concentrations of metformin used; 2 mM, 3 mM, and 4 
mM; a significant inhibition of adipogenesis was observed only with 4 
mM. Therefore, we decided to start all the future experiments with 2 
mM of metformin and increase the concentration two fold up to 16 mM 
i.e. 2 mM, 4 mM, 8 mM, and 16 mM. 
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3.1.2    Comparing 3T3-L1 lipid content at confluence (day 0) and at 
the end of adipogenesis (day 8) and after treatment with AICAR and 
metformin 
 
The amount of triglyceride in 3T3-L1 on day 0 and day 8 were compared 
by comparing the spectrophotometric readings of Oil red O on day 0 
and day 8. The results showed that the induction of adipogenesis 
resulted in a 3 fold increase in intracellular lipid content of 3T3-L1 
(figure 3.1). 
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Figure 3.1: the induction of adipogenesis increased the intracellular 
lipid content 3-fold from base line after eight days of adipogenesis, *p < 
0.05 day 0 vs day 8. AICAR and metformin significantly inhibit 
intracellular lipid accumulation in 3T3-L1, *p < 0.05 vs 0 mM after 8 
days of adipogenesis. Data expressed as mean ± SD, n = 6. 
     0         0       0        0        0        0        1 Concentration of AICAR (mM) 
 
     0         0        2        4        8      16       0 Concentration of metformin (mM)    
Days of adipogenesis 
* 
* 
* * 
* 
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Metformin at a concentration of 2 mM did not have any effect on the 
inhibition of triglyceride accumulation in 3T3-L1. However, significant 
inhibition of intracellular lipid was observed with 4, 8, and 16 mM of 
metformin (figure 3.1). It was also observed that the inhibition of lipid 
accumulation reached its peak at 8 mM (figure 3.1). Cells cultured with 
8 mM metformin had 45 % less lipid than the untreated cells. 
Cells treated with 1 mM AICAR also had significantly less intracellular 
lipid than the control cells. AICAR treated cells had approximately 35 % 
less lipid than the controls (figure 3.1). 
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3.1.3  Comparing protein concentrations of 3T3-L1 treated with 
metformin or AICAR and the control cells. 
 
Table 3.1: concentrations (in µg/mL) of protein extracts from 3T3-L1 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was no statistically significant difference between the protein 
concentrations from the control cultures and the protein concentration 
  
Negative 
control 
 
Metformin 
16 mM 
 
AICAR  
1mM 
 
Experiment 1 
 
259.4 
 
 
     540.8 
 
551.5 
 
Experiment 2 
 
473.5 
 
582.6 
 
329.0 
 
Experiment 3 
 
1610.3 
 
1461.9 
 
 
1239.4 
 
Experiment 4 
 
1416.7 
 
      963.6 
 
1222.1 
 
Experiment 5 
 
1529.9 
 
1236.6 
 
1175.6 
 
Mean 
 
1058.0 
 
957.1 
 
903.5 
 
Standard 
deviation 
 
639.5 
 
402.0 
 
430.8 
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from cells treated with metformin (p = 0.2367) (table 3.1). There was 
also no statistically significant difference between the protein 
concentration from the control cultures and the protein concentration 
from cells treated with AICAR (p = 0.1282) (table 3.1). The protein 
concentrations from metformin treated cells and AICAR treated cells, as 
well, did not show statistically significant difference (p = 0.6858) (table 
3.1).    
 
3.1.4  Western blotting for phospho-AMPK 
 
After 8 days of adipogenesis, the results of the Western blotting 
experiment of cells treated with 16 mM metformin and cells treated 
with 1 mM AICAR compared to controls suggested that there may be a 
relationship between the activation of AMPK and the accumulation of 
lipid in 3T3-L1. As shown in figure 3.2, there was a marked increase in 
the phosphorylation of AMPK in the presence of AICAR, and metformin, 
while the amount of phosphorylation in untreated cells remained 
comparable to phosphorylation on day 0.  
The net intensity of bands of AMPK phosphorylated at threonine 172 
(AMPK-Thr172) on day 8 for metformin, AICAR, and control cells were 
measured after each Western blotting experiment, using the Kodak 1D 
Image Analysis Software v3.6, and the results were plotted. AMPK 
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phosphorylation by metformin and AICAR was 4 to 5 fold higher than 
the phosphorylation of the enzyme in the control group (figure 3.3). 
        1.                2.                   3.                      4. 
 
Figure 3.2: Western blotting of total protein from 3T3-L1 on day 0 (lane 
1), from control 3T3-L1 cells on day 8 of adipogenesis (lane 2), and from 
3T3-L1 treated with AICAR and metformin (lane 3 and 4 respectively) on 
day 8. This blot is a representative of 5 different experiments. 
Polyclonal antibody specific to phospho-AMPK was used. 
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Figure 3.3: Comparison of the level of AMPK phosphorylation on day 8 
of adipogenesis, for metformin and AICAR treated cells versus controls, 
using the Kodak 1D Image Analysis Software v3.6. Data expressed as 
means ±  SD from 5 experiments, * p < 0.05 versus control cells. 
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3.2 U1 results 
3.2.1 Optimization of AICAR and metformin concentration for 
inhibition of HIV-1 replication in U1 cells  
 
There was no viable U1 cell after 48 hours of tissue culture with 1 mM 
AICAR (figure 3.4). A 50 % loss of viability was observed with U1 cells 
cultured with 0.5 mM AICAR (figure 3.4). 0.4 mM AICAR showed a very 
strong inhibition of HIV-1 replication (figure 3.5) and this concentration 
did not seem to be toxic to U1 cells (figure 3.4). For metformin the 
strongest inhibition of HIV-1 replication was observed with 16 mM 
(figure 3.5) and the viability of cells cultured with this concentration was 
comparable to that of the control culture (figure 3.4). The optimization 
experiment was carried out only once. The p24 concentrations obtained 
in this experiment were much higher then those obtained in the 
subsequent experiments. This could be attributed to differences in the 
cell passage number between experiments.      
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Figure 3.4: U1 Cell count after culturing the cells with metformin and 
AICAR and activating HIV-1 replication with 60 mM NaCl.  
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Figure 3.5. Determination of metformin and AICAR concentrations that 
had the strongest inhibition of HIV-1 replication in U1 cells. 
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3.2.2 NaCl activates HIV-1 replication in U1 cells 
 
The ability of 60 mM NaCl to induce HIV-1 replication in U1 cells was 
measured by comparing the rate of HIV-1 replication, after 2 days of 
tissue culture, between U1 cells treated with 60 mM NaCl and untreated 
U1 cells. The ELISA results indicated that 60 mM NaCl treated cells had 
an increase in HIV-1 replication of approximately 5 folds from baseline 
(figure 3.6).   
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Figure 3.6. U1 cells treated with 60 mM of NaCl have an increase in HIV-
1 replication of about 5 fold, compared to untreated cells. Data 
expressed as mean ± SD from 7 experiments; * p < 0.05 versus 
untreated cells. 
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3.2.3 AICAR and metformin inhibit  HIV-1 replication in U1 cells 
 
The results of p24 ELISA, after 48 hours of incubating the cells in 
medium containing AICAR or metformin, showed a marked inhibition of 
HIV-1 replication by both molecules. The concentration of p24 
decreased with increasing concentrations of either AICAR or metformin 
(figures 3.7 A and B). The means of p24 values as percentage of the 
control culture (cells cultured with 60 mM NaCl only) are also shown in 
table 3.2 for metformin, and table 3.3 for AICAR.  
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Figure 3.7: (A) Plot of P24 concentrations after 48 hours of HIV-1 
replication in U1 cells cultured with different concentrations of 
metformin. Data expressed as mean ± SD from 8 experiments; *p < 0.05 
versus 0 mM metformin. (B) P24 concentrations after 48 hours of HIV-1 
replication in U1 cells cultured with different concentrations of AICAR. 
Data expressed as mean ± SD from 9 experiments; *p< 0.05 versus 0 
mM AICAR. 
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Table 3.2: Mean p24 values as percentage of controls, after 2 days of 
tissue culture, for U1 cells treated with metformin. 
 
 
                                           P-value < 0.05, n = 8. 
 
 
 
 
 
 
Control 
cells 
Metformin 
4mM 
Metformin 
8mM 
Metformin 
16mM 
Mean 100.00 35.462 27.384 28.411 
Standard 
deviation 
0.00 17.065 8.718 9.961 
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Table 3.3: Mean p24 values as percentage of controls, after 2 days of 
tissue culture, for U1 cells treated with AICAR. 
 
 
                                    P-value < 0.05, n = 9. 
 
 
 
 
 
  
Control 
cells 
 
AICAR 
0.2mM 
 
AICAR 
0.35mM 
 
AICAR 
0.40mM 
 
Mean 
 
100.0 
 
 
61.7 
 
 
16.7 
 
14.1 
 
Standard 
deviation 
 
0.0 
 
 
32.8 
 
 
8.2 
 
10.5 
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3.2.4  AICAR and Metformin inhibit NF-kB translocation from the 
cytoplasm to the nucleus 
 
To determine whether the inhibition of HIV-1 replication by AICAR and 
metformin was due to the inhibition of NF- kB translocation from the 
cytoplasm to the nucleus, Western blotting of the cytoplasmic and 
nuclear extracts of U1 cells was performed. AICAR treated cells had the 
highest accumulation of NF- kB in their cytoplasm, followed by 
metformin treated cells, while the lowest amount of cytoplasmic NF- kB 
was observed in the control cells (figure 3.8 A). This experiment was 
repeated 3 times. 
In the nucleus the inverse of the cytoplasmic Western blots was 
observed. Control cells had the highest amount of NF- kB in their 
nucleus followed by metformin treated cells and AICAR treated cells had 
the lowest amount of NF- kB (Figure 3.8 B). 
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A. 
                 1.                             2.                       3.                                              
 
  
B. 
       1.                              2.                                  3. 
 
Figure 3.8: (A) Western blotting of the cytoplasmic extracts of U1 cells 
with anti-NF- kB antibody:  control cells, lane 1, metformin treated cells, 
lane 2; AICAR treated cells, lane 3. This is representative of 3 Western 
blots. 4 µg of protein were loaded in each well (B) Western blotting of 
the nuclear extracts of U1 cells with anti-NF- kB antibody: control cells, 
lane 1, metformin treated cells, lane 2, and AICAR treated cells, lane 3. 
This blot is representative of 5 Western blots. 4 µg of protein were 
loaded in each well. 
65 KDa 
65 KDa 
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The net intensity of the NF-kB bands on day 2 for metformin, AICAR, 
and control cells were measured after each Western blotting 
experiment, using the Kodak 1D Image Analysis Software v3.6 and the 
results were plotted. Although there was no statistical significance, the 
level of NF-kB in the cytoplasm of cells treated with metformin and 
AICAR was higher than the level of NF-kB in the cytoplasm of the control 
culture (figure 3.9 A). The graph of the nuclear NF-kB net intensities 
showed a significantly higher accumulation of the nuclear factor in the 
nucleus of the controls compared to metformin and AICAR treated cells 
(figure 3.9 B). 
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 Figure 3.9: (A) Comparison of the cytoplasmic level of NF-kB in 
metformin and AICAR treated cultures and control cells. Data is 
expressed as mean ± SD from 3 experiments. (B) Comparison of the 
nuclear level of NF-kB in metformin and AICAR treated cells and control 
cells. Data is expressed as mean ± SD from 5 experiments; *p < 0.05 
versus controls. 
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The membranes on which the cytoplasmic and the nuclear proteins were 
transferred were stained with amido black (figure 3.10 and 3.11). The 
results showed that an equivalent amount of protein was loaded in all 
but well 2 (lane 2) of figure 3.11. However, it is unlikely that this has 
interfered with the outcome of the experiment because the control 
culture (lane 1, figure 3.11) still had more nuclear NF-κB than metformin 
treated culture (lane 2, figure 3.11), see figure 3.8 (B) and 3.9 (B). 
 
           1.               2.                3.                4.                5.                                          
   
 
Figure 3.10: Amido black staining of the membrane used for Western 
blotting of the cytoplasmic extracts of U1 cells. Lane1 and 5, molecular 
weight markers; lane 2, control cells; lane 3, metformin treated cells; 
lane 4, AICAR treated cells.  
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          1.                      2.                         3.                      4.                                      
   
Figure 3.11: Amido black staining of the membrane used for Western 
blotting of the nuclear extracts of U1 cells. Lane 1, control cells; lane 2, 
metformin treated cells; lane 3, AICAR treated cells, lane 4, molecular 
weight markers.  
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3.2.5 AMPK expression in U1 cells 
 
Western blotting with antibody specific to the a-subunit of AMPK was 
performed to investigate whether AMPK was expressed in U1 cells. The 
results showed that the kinase is expressed in this cell line (figure 
3.12).  
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Figure 3.12:  Western blotting of U1 cells total protein with antibody 
specific to the α-subunit of AMPK. Lanes 1 and 5, molecular weight 
markers, lane 2 control cells, lane 3, metformin treated cells, and lane 
4, AICAR treated cells. This experiment was repeated twice, top and 
bottom membrane. 
       62 KDa 
       62 KDa 
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3.2.6   AICAR and metformin do not  phosphorylate AMPK at 
threonine 172 in U1 cells 
 
To show that metformin and AICAR inhibited the translocation of NF- kB 
via activation of AMPK, Western blotting with antibody specific to AMPK 
phosphorylated at Thr-172 was done with the cytoplasmic extracts of 
U1 cells. The antibody was unable to detect any phosphorylation of 
AMPK at Thr-172 after 48 hours of treatment with AICAR or metformin. 
The experimental time was reduced to 45 minutes to allow for the 
possibility that AMPK may have been dephosphorylated after 48 hours. 
After 45 minutes no phosphorylation of AMPK was observed. All these 
Western blots were repeated three times.  
We also verified whether the inability to observe the phosphorylation of 
AMPK was caused by the Western blotting method used. This was done 
by performing the Western blotting of phospho-AMPK in U1 cells 
(cultured with AICAR and metformin for 45 minutes) together with the 
western blotting for phospho-AMPK in 3T3-L1 (figure 3.13). The result 
showed that the inability to observe the phosphorylation of AMPK in U1 
cells was not due to the Western blotting method used, because 
phospho-AMPK could be detected in 3T3-L1 using the same method.  
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Figure 3.13: AMPK is phosphorylated in 3T3-L1 but not in U1 cells. Lane 1, 
3T3-L1 cultured without AICAR and metformin (controls or untreated cells); 
lane 2, 3T3-L1 cultured with AICAR, lane 3, 3T3-L1 cultured with metformin; 
lane 4 and 8, molecular weight markers; lane 5, U1 cells cultured with 60 mM 
NaCl only (controls); lane 6, U1 cells cultured with metformin; lane 7, U1 cells 
cultured with AICAR.  
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4.1 Metformin inhibits adipogenesis in 3T3-L1 
 
The present and a previous study [25] have both shown that AICAR 
inhibits adipogenesis in 3T3-L1 cells. This occurs by down-regulation of 
expression of the lipogenic enzymes ACC and FAS and of the 
adipogenic transcription factors peroxisome proliferator-activated 
receptor (PPAR)g and CCAAT/enhancer binding protein (C/EBP)a [25]. 
The present study is the first to demonstrate that the inhibition of intra-
cellular lipid accumulation in 3T3-L1 cells by AICAR or metformin is 
paralleled by increased phosphorylation of AMPK at residue Thr-172 of 
the catalytic a-subunit. The phosphorylation of AMPK at this site is 
essential for its function and activated AMPK is known to inhibit the 
lipogenic enzyme ACC by phosphorylation [83, 84]. 
This study demonstrates that culturing preadipocytes in the presence of 
metformin results in increased phosphorylation of AMPK at Thr-172 and 
accumulation of significantly less lipid than in non-treated cells. These 
data suggest that in 3T3-L1 cells undergoing adipogenesis, metformin 
activates AMPK, which in turn leads to the inhibition of intracellular lipid 
accumulation. This hypothesis is supported by an earlier study [9], 
showing that metformin treatment of rodent primary hepatocytes leads 
to AMPK activation, via increased phosphorylation at Thr-172, and 
inhibition of ACC activity. The inhibitory effect of metformin and AICAR 
on ACC activity was attenuated by an inhibitor of AMPK, compound C 
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[9]. Metformin inhibited gene expression of lipogenic enzymes FAS, and 
the lipogenic transcription factor, sterol regulatory enhancer binding 
protein (SREBP-1) [9]. These effects on gene expression were observed 
in both treated primary hepatocytes and in liver tissue isolated from 
rats treated with metformin [9]. Another study has also shown that 
treatment of the human hepatocyte cell line, HepG2, with metformin 
results in reduced intra-cellular lipid accumulation [38]. 
The present study suggests that metformin is able to reduce intra-
cellular lipid accumulation during adipogenesis by the activation of 
AMPK. Other studies show that this effect of AMPK may be due to the 
inhibition of lipogenic enzymes and the down regulation of 
transcription factors involved in lipogenesis [25] [1, 6]. Thus, the ability 
of metformin to limit weight gain in human subjects may be partially 
mediated by metformin’s actions on adipogenesis but it is probable that 
metformin may also inhibit lipid accumulation in mature adipocytes.  
However, this study does not show whether the activation of AMPK in 
adipose tissue was directly involved in the inhibition of lipid 
accumulation. There is still a possibility that the observed AMPK 
activation is simply a result of metformin altered cellular metabolism 
and has no involvement in the inhibition of lipid accumulation.  
Therefore, a study with inhibitors of AMPK, such as compound C [9] or 
AMPK specific small interfering RNAs (siRNAs), may be required to 
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confirm whether or not AMPK is involved in the metformin induced 
inhibition of intracellular lipid accumulation.  
It is also important to note that, although intracellular lipid 
accumulation is a key feature of adipogenesis, adipogenesis is a 
process that also involves the expression of genes such as PPARg, 
C/EBPa and C/EBPb [45]. Here we have simply shown that metformin 
inhibits one aspect of adipogenesis i.e. intra-cellular lipid accumulation 
and this inhibition is likely to be mediated by AMPK. However, it 
remains to be shown whether the activation of AMPK by metformin also 
involves the inhibition of the expression of pro-adipogenesis genes 
mentioned above.  
We are aware that the concentrations of metformin used to inhibit 
intracellular lipid accumulation by other researchers, such as Zhou et al. 
who used 0-2000 mM [9] were lower than the ones used in our study, 
2000-16000 mM. This difference may be attributed to the different 
tissues used in these studies. Thus, Zhou and co-workers worked on 
hepatocytes while our study was based on adipocytes.  
The possibility that the observed inhibition of intracellular lipid 
accumulation by metformin is due to toxicity to adipocytes cannot be 
ignored. Metformin has been reported to be toxic to the mitochondria 
[21]. Nevertheless, we have two main reasons to believe that the 
observed inhibition of lipid accumulation was not due to the toxicity of 
metformin to the cells. The first is that 3T3-L1are adherent cells i.e. 
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they grow by attaching to the surface of the flask in which they are 
cultured. When these cells lose their viability they detach from the 
surface. Because the experiment was performed over 8 days, with the 
medium being changed every two days, it would have been very easy to 
observe cell detachment. Secondly, the amount of protein extracted 
from the cells on day 8 does not suggest that metformin had a 
deleterious effect on cell growth. If metformin had killed the cells in 
culture, the amount of proteins extracted from the remaining cells 
would have been much smaller than the amount of protein extracted 
from untreated cells and AICAR treated cells. However, this was not the 
case (see table 3.1).  
It should also be mentioned that the finding that mannitol can activate 
AMPK by phosphorylation [34] raises some concerns as the cell lysis 
buffer used in the study contained mannitol (appendix II). However, if 
the observed phosphorylation of AMPK was caused by a reagent in the 
lysis buffer rather than by metformin or AICAR, it is clear that we would 
have observed a similar phosphorylation of AMPK in metformin, AICAR, 
and the control cells. However, as shown in figures 3.2 and 3.3, there 
was a clear difference in AMPK phosphorylation between the three 
groups.  
This study is the first to demonstrate a possible mechanism for the 
weight loss associated with the use of metformin in type 2 diabetic 
patients. The data presented in this report is complemented by another 
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study that shows the effects of AMPK activation by metformin on down 
stream enzymes, such as acetyl-CoA carboxylase and fatty-acid 
synthase, enzymes involved in fatty acid metabolism. As shown by 
Habinowsky and Witters [25] AMPK activation in 3T3-L1 with AICAR 
results in the inhibition of downstream enzymes involved in fatty acid 
biosynthesis.  
Finally, the use of AICAR as a positive control in this experiment is not 
ideal, for AICAR has been reported to target other intracellular enzymes, 
besides AMPK [25]. Nevertheless, AICAR is the most well known 
activator of AMPK and has been used in many studies of the AMPK 
signaling system [9, 25, 38]. It should also be mentioned that it would 
have been ideal to use a house keeping gene such as b-actin in our 
Western blotting experiments. However, it is also noted that similar 
studies [9] to ours have also not used house keeping genes to control 
for protein loading on Western blots.  
 
4.2 Metformin and AICAR inhibit HIV-1 replication in 
U1 cells 
 
In this report we have also been able to show that metformin and AICAR 
have inhibitory properties on HIV-1 replication in U1 cells. This 
inhibition is dose dependent i.e. increases as the concentration of these 
two molecules increases. A possible mechanism of inhibition of HIV-1 
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replication by AICAR and metformin is the inhibition of NF-kB 
translocation to the nucleus. This is shown by the increased 
accumulation of NF-kB in the cytoplasm of AICAR and metformin treated 
cells compared to the control cells and the reduced amount of this 
factor in the nuclei of these cells compared to the control cells. The 
absence of NF-kB in the nucleus results in the inhibition of HIV-1 gene 
transcription. However, it is still unclear which enzyme mediates the 
inhibition of NF-kB translocation to the nucleus. AICAR and metformin 
are well known activators of AMPK, and the enzyme is expressed in U1 
cells, as shown in figure 3.12. However, we failed to observe any 
phosphorylation of the kinase by both drugs.   
Our study therefore suggests that in monocytes, both AICAR and 
metformin do not activate AMPK or they do via a mechanism other than 
phosphorylation at threonine 172 of the a-subunit. Under the belief that 
AICAR and metformin did activate AMPK by phosphorylation and that 
this phosphoprylation might have lasted for only a short period of time, 
we set up the same experiment but for a much shorter duration i.e. 45 
minutes instead of 48 hours. However, we still did not manage to 
observe any phosphorylation of AMPK in these cells by either molecule. 
It may also be argued that AMPK phosphorylation was complete in 5 
minutes that is why we couldn’t detect any phosphorylation after 45 
minutes. A counter argument to this, however, is that in 3T3-L1 the 
enzyme remains phosphorylated even 48 hours after activation. It is 
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also unlikely that a phosphorylation that lasted only few minutes will 
have such a strong effect on HIV replication after 48 hours.   
The fact that phospho-AMPK couldn’t be detected does not mean that 
AMPK phosphorylation may not play a role in the inhibition of NF-kB 
translocation to the nucleus, in U1 cells. The best way to confirm the 
involvement of AMPK in the inhibitory pathway of NF-kB translocation to 
the nucleus is by either using one of the pharmacological inhibitors of 
AMPK e.g. compound C [9] or adenine 9-b-D-arabinofuranosine [75] or 
siRNAs, which are more specific inhibitors of the enzyme.  It is 
noteworthy that a study by Guigas et al. [85] showed that AICAR and 
metformin could inhibit the glucose induced translocation of 
glucokinase from the nucleus to the cytosol via an AMPK independent 
mechanism. Guigas et al. proposed the decrease in intracellular ATP 
concentrations to be responsible for this inhibition [85].  
It is possible that the inhibition of HIV-1 replication by AICAR and 
metformin was simply due to the toxic effects of these drugs to U1 
cells. However, our results (figure 3.4) show that U1 cells cultured with 
AICAR and metformin, at the concentrations used in the study, had 
comparable viability to U1 cells cultured without AICAR or metformin. 
We should also mention that we obtained high standard deviations 
between different experiments in this study, which is one of the set 
backs of the study. We believe this is most probably due to the 
difference in the cell passage number for different experiments. 
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Nevertheless, the difference in the p24 concentrations between 
metformin or AICAR treated cells when compared to the control group 
was statistically significant. It can also be argued that the difference in 
cytoplasmic and nuclear NF-kB was simply due to unequal amount of 
proteins loaded in each well of the gel. However, it should be noted that 
our Western blotting experiments were repeated at least 3 times to 
minimize such a possibility. Also the Bradford method was used to 
determine the protein concentrations, we believe if there is no error in 
the calculations it is possible to load the same amount of protein in 
different wells of the gel.  
NF-kB plays an important role in the initiation of HIV-1 gene 
transcription [7, 63, 73]. HIV-1 LTR is made of two highly conserved 
copies of the kB elements [63] which are crucial for RNA transcription of 
the integrated provirus. However, there are some major differences in 
the HIV-1 and HIV-2 genome [56, 86]. These two viruses rely on 
different enhancers to control their gene transcription. Hannibal and 
colleagues showed that TNF-a activation of HIV-1, which is mediated by 
NF-kB binding to the kB element, is many fold higher than the activation 
of HIV-2 [86]. Most importantly, Hannibal and his group reported that 
while HIV-1 gene transcription relies solely on NF-kB, there are other 
factors that also regulate gene transcription in HIV-2 [86]. This suggests 
that metformin and AICAR may not have a significant inhibitory activity 
against HIV-2.  
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Our results suggest the possibility of using AICAR and metformin to 
treat HIV-1 infection. This by preventing latently infected cells becoming 
sites of HIV-1 replication, via inhibition of the transcription factor 
needed for HIV-1 gene transcription. Since these compounds modify the 
host’s response rather than directly target the virus, they may also be 
less vulnerable to the high rate of mutations taking place in the viral 
genome. 
Lastly, not only is metformin or AICAR relatively cheap when compared 
to existing antiretrovirals, they are also less toxic. For example the 
overall incidence of lactic acidosis associated with metformin is about 
0.05 cases per 1000 patients per year [22], and AICAR is safely used to 
treat ischemic heart disease [28, 29]. Furthermore, metformin has been 
successfully used to treat lipodystrophy in HIV positive patients [87] 
with no negative side effects. However, this study did not look at the 
viral loads of these patients as they were also being treated with anti-
retrovirals, which could mask the effects of metformin. The toxicity of 
antiretrovirals has already been discussed in section 1.7.10. 
In conclusion, metformin and AICAR reduce intracellular lipid 
accumulation in the 3T3-L1 cells, most probably by activation of AMPK. 
Furthermore, both these agents are able to inhibit HIV-1 replication in 
U1 cells, and this may occur via down regulation of nuclear NF-kB levels. 
The involvement of AMPK in this process is not certain.  
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APPENDIX I 
REAGENTS 
 
Dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), AICAR and 
metformin were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). 
Insulin was supplied by Novo Nordisk (Copenhagen, Denmark).  The 
Dulbecco modified Eagle’s medium (DMEM), foetal calf serum (FCS), 
penicillin, streptomycin, trypsin, sodium pyruvate, and L-glutamine were 
purchased from Gibco-Invitrogen, (Carlsbad, California, USA). RPMI 1640 
came from Biowhittaker, Walkersville, U.S.A. The phospho-AMPK 
(Thr172) and the pan a AMPK antibodies were obtained from Cell 
Signaling Technology, Inc. (Beverly, Massachusetts, USA). Goat anti-
rabbit-HRP antibody, used as secondary antibody against phospho-
AMPK, was obtained from DakoCytomation (Glostrup, Denmark). Rabbit 
anti-sheep-HRP antibody, used as secondary antibody against pan a 
AMPK antibody, also came from DakoCytomation, (Glostrup, Denmark). 
The antibody specific to NF-kB was supplied by EMD Biosciences, Inc., 
an affiliate of Merck KGaA (Darmstradt, Germany). The goat anti-rabbit-
HRP antibody used as secondary antibody against NF-kB came from 
DakoCytomation (Glostrup, Denmark). The enhanced chemiluminescent 
(ECL) reagents, Hybond-P PVDF membrane, ECLTM detection reagents and 
Hyperfilm ECL, were provided by Amersham Biosciences UK Limited 
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(Little Chalfont, Buckinghamshire, UK). The Oil red O dye came from 
Sigma-Aldrich (St. Louis, Missouri, USA). Low passage number 3T3-L1 
cell line, pre-adipocytes that can be transformed into adipocytes, were 
obtained from the European Collection of Cell Cultures (number 
86052701). The U1 cell line, HIV-1 chronically infected monocytes, was 
obtained from the NIH AIDS Research and Reference Reagent Program, 
NIAID. Trans-blot filter papers were from Biorad (Hercules, California, 
USA). Molecular weight markers Kaleidoscope prestained standards 
were from Biorad (Hercules California). NucBuster used to extract total 
nuclear and cytoplasmic protein was from EMD Biosciences, Inc., an 
affiliate of Merck KGaA (Darmstradt, Germany). The p24 assay kit came 
from Dupont (DuPont, Boston, MA). Trypan blue was purchased from 
Sigma-Aldrich (St. Louis, Missouri, USA). 
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APPENDIX II 
BUFFERS AND SOLUTIONS FOR PROTEIN 
ELECTROPHORESIS AND WESTERN BLOTTING 
 
Composition of DMEM maintenance medium: 
 
100mL of maintenance medium:  
DMEM                           1.35 g  
Sodium bicarbonate     0.37 g  
Fetal calf serum         10.0 mL  
Penicillin                       100 U 
Streptomycin                100 U  
Sodium pyruvate           1 mM  
L-glutamine                   2 mM   
 
Stacking gel buffer (pH 6.8):  
 
0.5M tris-HCl: 
Tris                                6 g 
Water                         40 mL 
Take the pH to 6.8 with hydrochloric acid (2 M). Make up to 100 mL 
with water. 
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Resolving gel buffer: 
 
Tris                      36.3 g 
HCl (2M)               24 mL 
Water                  100 mL 
 
Stock reservoir buffer (pH 8.3):  
 
Tris                      3.03 g 
Glycine                 14.4 g 
SDS                        1 g 
Water                      1 L 
 
Ammonium persulphate solution (3%): 
 
300 mg of ammonium persulphate in 10 mL of water. 
Note that the ammonium persulphate must be freshly made before use. 
 
Stock acrylamide bis solution: 
 
Acrylamide                          30 g 
Bisacrylamide                      0.4 g 
Water                                  100 mL 
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Filter with a Whatman filter paper, cover with foil and store in the fridge. 
 
Sodium dodecyl sulphate solution (SDS) (10%): 
 
Sodium dodecyl sulphate      1 g 
Water                                   10 mL 
 
SDS gel preparation: 
Resolving gel: 
 
Acrylamide/Bis                     8.3 mL 
Resolving buffer                   2.5 mL 
10%   SDS                             0.2 mL 
1.5% ammonium persulfate     1 mL 
Water                                   9.6 mL 
TEMED                                   10 µL 
Note: the gel should be de-aerated prior to addition of ammonium 
persulfate. 
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Stacking gel: 
 
Acrylamide/Bis solution       2.5 mL 
Stacking gel buffer                 5 mL 
10%   SDS                            0.2 mL 
1.5% Ammonium persulfate 1.0 mL 
TEMED                                  15 µL 
Water                                 11.3 mL 
Note: the gel should be de-aerated before addition of ammonium 
persulfate. 
 
Reducing solution and gel loading buffer for gel electrophoresis: 
 
Sodium dodecyl sulphate      1 g 
ß-Mercaptoethanol                2 mL 
Bromophenol blue                10 mg 
Stacking buffer stock            1.5 mL 
Sucrose                                 5 g 
Water                                     6.5 mL 
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Tris buffered saline-Tween (TBS-T) 20 (pH 7.4): 
 
Tris                                     1.21 g 
NaCl                                    8.27 g 
Tween-20                               1 mL 
Water                                        1 L 
 
Transfer buffer: 
 
Tris                                       3.03 g 
Glycine                                  43.2 g 
Methanol                              200m L 
Water                                           1 L 
 
Phosphate buffered saline (PBS) (pH 7.4): 
 
NaCl                                              8g  
KCl                                            0.2 g 
Na
2
HPO
4  
                                 1.81 g 
KH
2
PHO
4
                                  0.24 g  
In 900 mL of milli-Q water, adjust the pH to 7.4 using HCl, and make up 
the solution to 1 L. 
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Krebs-HEPES Buffer (pH 7.4): 
 
NaHEPES                                  5.2 g  
NaCl                                         6.9 g  
KCl                                         0.26 g 
CaCl
2
                                      0.19 g 
MgSO
4
                                    0.14 g 
KH
2
PO
4
                                    0.21 g 
Glucose                                  1.80 g  
0.1% (w/v) bovine serum albumin 
Water                                      1 Liter 
 
3T3-L1 Lysis buffer (pH 7.4): 
 
Tris/HCl                                             14.3 g 
 NaF                                                     2.1 g 
 Na
4
0
7
P
2
.10H
2
O                                      2.2 g  
 EDTA                                                 0.29 g  
 EGTA                                                 0.38 g 
 Mannitol                                            45.6 g 
 Triton X-100                                   1% (v/v) 
 Dithiothreitol                                     0.15 g 
 Benzamidine                                      0.16 g 
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 phenylmethane sulfonyl fluoride    0.0174 g 
Soybean trypsin inhibitor                      5 mg 
Water                                                 1 Liter 
 
Coomassie reagent: 
 
Coomassie G-250                                100 mg 
95% ethanol                                          50 mL 
85% phosphoric acid                           100 mL 
Distilled water                                     850 mL 
This solution should be stirred, filtered and stored in a dark bottle. 
 
Reagents for amido black staining 
 
Stain: 
0.1% (w/v) amido black in 25% (v/v) isopropanol, 10% (v/v) acetic acid, 
in water;  
Destain solution:  
25% (v/v) isopropanol, 10% (v/v) acetic acid in water. 
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Metformin stock solution for the adipogenesis experiment: 
 
1 M metformin solution: 
Metformin (Molecular weight 165.63 g/mole) 1.66 g  
3T3-L1 cells growth medium                          10 mL 
 
AICAR stock solution for the adipogenesis experiment: 
 
0.1M AICAR solution: 
 AICAR (Molecular weight 258.2g/mole)         0.258 g  
3T3-L1 cells growth medium                             10 mL  
 
Metformin stock solution for the HIV-1 inhibition experiment: 
 
1 M metformin solution: 
Metformin                                                      1.66 g  
PBS                                                                 10 mL 
 
AICAR stock solution for the HIV-1 inhibition experiment: 
 
0.1 M AICAR:                           0.258 g  
PBS                                             10 mL 
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IBMX solution:  
IBMX                                          50 mg  
Warm methanol                            1 mL   
 
Dexamethasone solution:  
Dexamethasone                        10 mg  
Ethanol                                      10 mL 
PBS                                            190 mL  
Note: the PBS was filtered with a Whatman paper before use. 
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APPENDIX III 
RAW DATA 
 
Table 1: Absorbance readings of Oil red O on day 0 and day 8 of 3T3-L1 
tissue culture. 
  
Day 0 
 
Day 8 
 
Experiment 1 
 
0.0250 
 
0.1161 
 
Experiment 2 
 
0.0303 
 
0.0942 
 
Experiment 3 
 
0.0300 
 
0.1004 
 
Experiment 4 
 
0.0230 
 
0.0846 
 
Experiment 5 
 
0.0444 
 
0.0635 
 
Experiment 6 
 
0.0247 
 
0.0574 
 
Mean 
 
0.0296 
 
0.0860 
 
Standard deviation 
 
0.0079 
 
0.0224 
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Table 2: Absorbance readings of Oil red O for different concentrations 
of Metformin on day 8. 
  
0 mM 
 
2 mM 
 
4 mM 
 
8 mM 
 
16 mM 
 
Experiment 1 
 
0.1161 
 
.1509 
 
 
.0936 
 
 
.0648 
 
 
.0604 
 
 
Experiment 2 
 
0.0942 
 
.1005 
 
 
.0794 
 
 
.0635 
 
 
.0651 
 
 
Experiment 3 
 
0.1004 
 
.1035 
 
 
.0768 
 
 
.0520 
 
 
.0555 
 
 
Experiment 4 
 
0.0846 
 
.0768 
 
 
.0405 
 
 
.0400 
 
 
.0271 
 
 
Experiment 5 
 
0.0635 
 
.0520 
 
 
.0368 
 
 
.0377 
 
 
.0365 
 
 
Experiment 6 
 
0.0574 
 
.0555 
 
.0161 
 
.0333 
 
.0385 
 
Mean 
 
0.0860 
 
.0899 
 
 
.0572 
 
 
.0486 
 
 
.0472 
 
 
Standard deviation 
 
0.0224 
 
.0369 
 
 
.0303 
 
 
.0136 
 
 
.0152 
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Table 3: Absorbance readings of Oil red O of 0 mM and 1 mM of AICAR 
on day 8. 
  
0 mM 
 
1 mM 
 
Experiment 1 
 
.1161 
 
 
.0757 
 
 
Experiment 2 
 
.0942 
 
 
.0690 
 
 
Experiment 3 
 
.1004 
 
 
.0701 
 
 
Experiment 4 
 
.0846 
 
 
.0475 
 
 
Experiment 5 
 
.0635 
 
 
.0512 
 
 
Experiment 6 
 
.0574 
 
.0473 
 
Mean 
 
.0860 
 
 
.0601 
 
 
Standard deviation 
 
.0224 
 
 
0128 
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Table 4: Kodak ID Image Analysis v3.6 net intensity values of phospho-
AMPK on day 8 of adipogenesis. For AICAR 1 mM, metformin 16 mM, 
and the negative control. 
 
 
 
  
AICAR 
 
Metformin 
 
Negative control 
 
Experiment 1 
 
16785.030 
 
 
33116.450 
 
 
8291.230 
 
Experiment 2 
 
56277.480 
 
 
31080.280 
 
 
11880.640 
 
Experiment 3 
 
15245.830 
 
 
81197.310 
 
 
11473.500 
 
Experiment 4 
 
90933.280 
 
 
28749.790 
 
 
4731.070 
 
Experiment 5 
 
200949.650 
 
 
303491.000 
 
 
52333.740 
 
Mean 
 
76038.254 
 
 
95526.966 
 
 
17742.036 
 
Standard deviation 
 
76521.027 
 
 
118281.463 
 
 
19550.188 
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Table 5: P24 values for NaCl treated cells and untreated cells on day 2 
of tissue culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
NaCl treated 
cells 
 
Untreated cells 
 
Experiment 1 
 
16.8000 
 
 
2.2250 
 
 
Experiment 2 
 
2.1760 
 
 
0.950 
 
 
Experiment 3 
 
0.6820 
 
 
0.1310 
 
 
Experiment 4 
 
0.7120 
 
 
0.2630 
 
 
Experiment 5 
 
1.5320 
 
 
0.4180 
 
 
Experiment 6 
 
1.0090 
 
0.2630 
 
Experiment 7 
 
1.4470 
 
0.3360 
 
Mean 
 
3.480 
 
 
5.897 
 
 
Standard deviation 
 
0.655 
 
 
0.741 
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Table 6: P24 values in ng/mL for the control culture and 4, 8, and 16 
mM metformin treated cultures, after 2 days of tissue culture. 
 
 
 
  
Control 
cells 
 
Metformin 
4 mM 
 
Metformin 
8 mM 
 
Metformin 16 
mM 
 
Experiment 1 
 
5.569 
 
 
2.219 
 
 
1.456 
 
1.484 
 
Experiment 2 
 
55.989 
 
 
26.637 
 
 
20.980 
 
13.206 
 
Experiment 3 
 
1.725 
 
 
0.442 
 
 
0.405 
 
0.394 
 
Experiment 4 
 
1.156 
 
 
0.634 
 
 
0.378 
 
0.461 
 
Experiment 5 
 
4.799 
 
 
2.811 
 
 
1.735 
 
2.097 
 
Experiment 6 
 
1.447 
 
0.226 
 
0.163 
 
0.173 
 
Experiment 7 
 
2.176 
 
0.351 
 
0.462 
 
0.625 
 
Experiment 8 
 
0.682 
 
0.174 
 
0.209 
 
0.204 
 
Mean 
 
9.193 
 
 
4.187 
 
 
3.224 
 
2.330 
 
Standard 
deviation 
 
18.990 
 
 
9.126 
 
 
7.199 
 
4.446 
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Table 7: P24 values, in table 6, expressed as percentage of the control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Control 
cells 
 
Metformin 
4 mM 
 
Metformin 
8 mM 
 
Metformin 16 
mM 
 
Experiment 1 
 
100.00 
 
 
39.84 
 
 
26.14 
 
26.64 
 
Experiment 2 
 
100.00 
 
 
47.57 
 
 
37.47 
 
23.59 
 
Experiment 3 
 
100.00 
 
 
25.62 
 
 
23.48 
 
22.84 
 
Experiment 4 
 
100.00 
 
 
54.84 
 
 
32.70 
 
39.89 
 
Experiment 5 
 
100.00 
 
 
58.57 
 
 
36.15 
 
43.70 
 
Experiment 6 
 
100.00 
 
15.62 
 
11.26 
 
12.00 
 
Experiment 7 
 
100.00 
 
16.13 
 
21.23 
 
28.72 
 
Experiment 8 
 
100.00 
 
25.51 
 
30.64 
 
29.91 
 
Mean 
 
100.00 
 
 
35.462 
 
 
27.384 
 
28.411 
 
Standard 
deviation 
 
0.00 
 
 
17.065 
 
 
8.718 
 
9.961 
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Table 8: P24 values in ng/mL for the control U1 culture, 0.2 mM, 0.35 
mM, and 0.4 mM AICAR treated U1 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Control 
cells 
 
AICAR 0.2 
mM 
 
AICAR 
0.35 mM 
 
AICAR 0.4 
mM 
 
Experiment 1 
 
1.156 
 
 
0.618 
 
0.113 
 
0.101 
 
Experiment 2 
 
5.569 
 
 
6.058 
 
 
1.539 
 
1.449 
 
Experiment 3 
 
16.376 
 
 
7.805 
 
 
1.482 
 
0.266 
 
Experiment 4 
 
55.939 
 
 
10.566 
 
 
2.721 
 
1.965 
 
Experiment 5 
 
4.797 
 
 
2.413 
 
 
1.337 
 
1.422 
 
Experiment 6 
 
1.725 
 
0.555 
 
0.262 
 
0.255 
 
Experiment 7 
 
0.682 
 
0.755 
 
0.157 
 
0.162 
 
Experiment 8 
 
2.176 
 
1.884 
 
0.307 
 
0.128 
 
Experiment 9 
 
1.447 
 
0.673 
 
0.268 
 
0.168 
 
Mean 
 
9.985 
 
 
3.481 
 
 
0.910 
 
0.657 
 
Standard 
deviation 
 
17.908 
 
 
3.730 
 
 
0.907 
 
0.734 
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Table 9: P24 values, in table 8, expressed as percentage of the control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Control 
cells 
 
AICAR 0.2 
mM 
 
AICAR 0.35 
mM 
 
AICAR 0.40 mM 
 
Experiment 1 
 
100.0 
 
 
53.5 
 
 
9.8 
 
8.7 
 
Experiment 2 
 
100.0 
 
 
108.7 
 
 
27.6 
 
27.6 
 
Experiment 3 
 
100.0 
 
 
47.7 
 
 
9.0 
 
1.6 
 
Experiment 4 
 
100.0 
 
 
18.9 
 
 
4.9 
 
3.5 
 
Experiment 5 
 
100.0 
 
 
50.3 
 
 
27.9 
 
29.6 
 
Experiment 6 
 
100.0 
 
32.2 
 
15.2 
 
14.8 
 
Experiment 7 
 
100.0 
 
111.0 
 
23.0 
 
23.8 
 
Experiment 8 
 
100.0 
 
86.6 
 
14.1 
 
5.9 
 
Experiment 9 
 
100.0 
 
46.5 
 
18.5 
 
11.6 
 
Mean 
 
100.0 
 
 
61.7 
 
 
16.7 
 
14.131 
 
Standard 
deviation 
 
0.0 
 
 
32.8 
 
 
8.2 
 
10.5 
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Table 10: Kodak 1D Image Analysis Software v3.6 net intensity values 
for nuclear NF-kB in U1 cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Untreated 
cells 
 
Metformin 
16 mM 
 
AICAR 0.40 
mM 
 
Experiment 1 
 
575358.290 
 
 
256588.460 
 
106952.000 
 
Experiment 2 
 
120091.680 
 
15080.930 
 
22492.000 
 
Experiment 3 
 
10843.640 
 
8612.590 
 
9744.980 
 
Experiment 4 
 
41714.930 
 
13671.830 
 
9897.220 
 
Experiment 5 
 
81529.000 
 
40703.000 
 
18228.50 
 
Mean 
 
165907.508 
 
140736.498 
 
33462.940 
 
Standard 
deviation 
 
232560.404 
 
166947.786 
 
41445.677 
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Table 11: Kodak 1D Image Analysis Software v3.6 net intensity values 
for cytoplasmic NF-kB in U1 cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Untreated 
cells 
 
Metformin 16 
mM 
 
AICAR 0.40 
mM 
 
Experiment 1 
 
6323.490 
 
 
2579.370 
 
14703.930 
 
Experiment 2 
 
150924.640 
 
163644.820 
 
237380.230 
 
Experiment 3 
 
155612.000 
 
217561.480 
 
332234.920 
 
Mean 
 
104286.710 
 
127928.557 
 
194773.027 
 
Standard 
deviation 
 
84871.003 
 
111852.874 
 
162996.972 
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Table 12: concentration (µg/mL) of protein extracts from U1 cells 
cytoplasm. 
          
             
  
Negative 
control 
 
Metformin 
16 mM 
 
AICAR  
1 mM 
 
Experiment 1 
 
2083.0 
 
 
     1362.4 
 
    1449.4 
 
Experiment 2 
 
1958.3 
 
1696.0 
 
1638.6 
 
Experiment 3 
 
1782.0 
 
1588.8 
 
 
1840.41 
 
Experiment 4 
 
641.6 
 
      680.3 
 
523.1 
 
Experiment 5 
 
607.1 
 
527.0 
 
626.1 
 
Mean 
 
1414.4 
 
1170.9 
 
1215.5 
 
Standard 
deviation 
 
729.2 
 
534.4 
 
602.3 
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 Table 13: concentration (µg/mL) of protein extracts from U1 cells 
nucleus. 
 
  
Negative 
control 
 
Metformin 
16 mM 
 
AICAR  
1 mM 
 
Experiment 1 
 
1506.6 
 
 
     1184.3 
 
2337.8 
 
Experiment 2 
 
1177.5 
 
1067.7 
 
687.9 
 
Experiment 3 
 
2399.2 
 
1054.6 
 
 
1200.8 
 
Experiment 4 
 
544.1 
 
      477.6 
 
570.6 
 
Experiment 5 
 
293.4 
 
481.9 
 
603.4 
 
Mean 
 
1184.1 
 
853.2 
 
1080.1 
 
Standard 
deviation 
 
834.2 
 
344.7 
 
747.8 
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